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Abstract: Routine manipulation of the mouse genome has become a landmark in biomedical research.
Traits that are only associated with advanced developmental stages can now be investigated within a
living organism, and the in vivo analysis of corresponding phenotypes and functions advances the
translation into the clinical setting. The annexins, a family of closely related calcium (Ca2+)- and lipid-
binding proteins, are found at various intra- and extracellular locations, and interact with a broad
range of membrane lipids and proteins. Their impacts on cellular functions has been extensively
assessed in vitro, yet annexin-deficient mouse models generally develop normally and do not display
obvious phenotypes. Only in recent years, studies examining genetically modified annexin mouse
models which were exposed to stress conditions mimicking human disease often revealed striking
phenotypes. This review is the first comprehensive overview of annexin-related research using
animal models and their exciting future use for relevant issues in biology and experimental medicine.
Keywords: annexins; calcium; human disease models; KO mice; membrane trafficking; membrane
organization; extracellular annexin functions
1. Introduction
The assembly of the human genome, followed by DNA deep sequencing, changed
our approach to analyse gene functions. Genetic tools, which helped to develop a major
part of our understanding of modern biology, started off with phenotypes and aimed to
identify the underlying gene or its allelic variation to infer function. The completion of
the human genome assembly marked the onset of methods that build on reverse genetics.
Genes and their genomic sequence became available and the generation of mouse models
with gene deletions or targeted mutations allowed the in vivo analysis of corresponding
phenotypes and functions.
Mouse models lacking individual members of the annexin gene family have been
established and unravelled some of their in vivo functions. There are many excellent re-
views on the annexin family covering the common and specific characteristics of individual
annexin family members [1–13]. Hence, in the following, we provide only a brief overview
necessary to appreciate the generation and functional implications from the in vivo analysis
of the annexin mouse models.
The annexin family consists of twelve evolutionary conserved and structurally related
Ca2+- and phospholipid-binding proteins [1,14]. All annexins are structurally related,
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they encode a variable N-terminal domain, which is responsible for different, annexin
member-specific functions, and a highly conserved C-terminal core. The C-terminal do-
main is composed of four highly related repeats (eight in case of AnxA6) containing Ca2+
binding sites that enable the interaction with negatively charged phospholipids (Figure 1).
Extensive in vitro analysis solved the three-dimensional structures of annexins ([15–18],
reviewed in [2,19,20]), their Ca2+-dependent affinities to various phospholipids and other
interaction partners [1,2]. A large number of regulatory roles associated with individual
annexins can be explained by their Ca2+-inducible and rapid translocation from the cytosol
to the plasma membrane or intracellular membranes [1–4]. At these locations, their unique
N-termini interact with dissimilar binding partners, which in part explains the functional
diversity of annexins. In addition, the composition and distribution of phospholipids
and other lipids, such as phosphatidylinositol-4,5-bisphosphate, cholesterol and ceramide
within specific membrane microdomains, but also posttranslational modifications and
pH, contribute to different spatiotemporal and Ca2+-sensitive membrane binding kinetics
leading to further functional diversification of individual family members [1–9,11].
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These processes are thought to control basic cellular functions that are pivotal to
the regulation of growth, d velopment, programm d cell death, but also c ll motility,
membrane repair and inflammatory response [1–13]. Ectopic overexpression or siRNA-
mediated knockdown delivered great insights in the annexin biochemistry and broadened
our knowledge substantially. More advanced technologies of reverse genetics made knock-
out (KO) mouse models the gold standard to analyse annexin functions. During the last two
decades KO-mice strains with targeted deletion of several annexins (i.e., AnxA1, A2, A4,
A5, A6, A7 and A8) have been successfully generated and provide an important research
tool to the community (Figure 1). All but one of these mice strains did not display any
obvious phenotype and developed entirely normal. Given the high degree of conservation
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this outcome was not anticipated and suggested that potentially individual members of
the annexin gene family could functionally substitute for each other and hence might be
redundant. However, annexin KO-mice or wildtype mice with implanted annexin KO-cells
developed strong phenotypes when analysed in stress conditions that mimicked certain
disease [10]. Additionally, the observed phenotypes were specific to individual annexins; a
finding which strongly argued against functional redundancy of individual gene family
members. In fact, as outlined further below, annexins in general might provide a toolbox
to cope with cell stress and pathogen attack [12,13]. Of late, a substantial number of new
studies exploring human disorders in annexin KO-models further emphasize their great
therapeutic value and the suitability of whole-body annexin KO-mice or animals implanted
with annexin-deficient cell lines to investigate a wide range of human diseases.
The following sections address individual annexins and their corresponding functions
in rodent and other animal models in vivo.
2. AnxA1
AnxA1 is expressed in most cells and tissues, being highly prominent in macrophages,
neutrophils, the nervous and endocrine system [1,2,10,21,22]. Inside cells, AnxA1 is lo-
cated at the plasma membrane, endosomal and secretory vesicles, but also at cytoskeletal
elements and in the nucleus. At these sites, AnxA1 contributes to the regulation of endo-
and exocytosis, signal transduction, cellular metabolism, and cytoskeletal rearrangements,
all relevant for proliferation, differentiation, migration, survival, but also repair, inflamma-
tion and viral infection [1–3,5,6,11]. In addition, upon glucocorticoid stimulation, AnxA1 is
secreted from cells, possibly via non-conventional pathways [1,21,22], delivering substan-
tial amounts of AnxA1 to the extracellular space that drive the multiple anti-inflammatory
aspects of glucocorticoid action [1,21–23].
2.1. AnxA1 and the Anti-Inflammatory Response
An extensive body of work has linked AnxA1 with the regulation of inflammatory
processes. Examining glucocorticoid-dependent activation of innate immune cells in
the AnxA1 KO-mice (Anxa1−/−) provided the first in vivo evidence that AnxA1 limits
pro-inflammatory response [24] (Table 1a). Complementing earlier in vivo studies ad-
ministering recombinant AnxA1 [23,25], Anxa1−/− mice displayed a boosted immune
response characterized by an increased leucocyte migratory behaviour and a substantial
resistance to the anti-inflammatory action of glucocorticoids in several acute inflammation
models [24]. Mechanistically, in carrageenan-induced paw oedema and zymosan-induced
peritonitis, the prominent ability of AnxA1 to counteract inflammatory events occured
through binding of extracellular AnxA1 to formyl peptide receptors (FPRs), a family of
G-protein coupled receptors found on many cells of the innate immune system, including
neutrophils and monocytes [26,27]. The AnxA1/FPR2 axis inhibits neutrophil recruitment
to sites of inflammation, a critical step in the regulation of inflammation [28]. In addi-
tion, AnxA1 increases neutrophil apoptosis and recruitment of monocytes, which upon
differentiation [29], allow clearance of apoptotic cells. The latter might be mediated by
locally produced steroids, including estrogens, which promote production and release of
AnxA1 [30]. Furthermore, the ability of AnxA1 to reduce production of pro-inflammatory
mediators, such as eicosanoids, nitric oxide, and interleukins (ILs) also contributes to
resolve inflammation.
The AnxA1/FPR2 axis is now well believed to elicit anti-inflammatory activity through
multiple signaling modules, including mitogen-activated protein kinases (MAPK) such
as extracellular signal-regulated kinases 1/2 and p38MAPK, as well as protein kinase B
(Akt), c-Jun N-terminal kinase, and intracellular Ca2+ elevation. Several chemokine recep-
tors [31,32] and transcription factors also act downstream the AnxA1/FPR2 pathway [22,33].
Given the enormous variety of experimental mouse models to study inflammation, we
recommend excellent reviews [21–23,25,33–36] for a more comprehensive list of studies
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that utilized the AnxA1−/− strain to corroborate the anti-inflammatory roles of AnxA1
(Table 1a,b).
Several recent studies have provided additional mechanistic insights. Mast cells criti-
cally mediate early lipopolysaccharide-induced neutrophil recruitment, a FPR2-dependent
process that can be blocked by AnxA1-derived peptides [37]. Along these lines, in
ovalbumin-induced atopic dermatitis-like skin lesions, AnxA1 is responsible for the pro-
duction of allergen-induced immunoglobubin E, cytokines as well as the recruitment of
inflammatory cells, in particular mast cells, to the lesion site [38]. Other studies identi-
fied mast cell stabilizers to treat ocular allergy, such as cromoglycate and nedocromil, to
promote cellular AnxA1 release, which limits mast cell degranulation and the extend of
the allergen-mediated allergic reactions [39,40]. Interestingly, AnxA1 not only impacts on
neutrophil homeostasis in the presence of glucocorticoids, but also seems to modulate
steady-state neutrophil maturation [31]. In efforts to clarify the role of exogenous AnxA1
for the hematopoietic system, administration of AnxA1, most likely via FPR-induced Ca2+
and MAPK signalling, promotes myeloid and granulocytic differentiation [41].
Adding further complexity, antigen presentation and T cell activation are also modulated
by the AnxA1/FPR2 axis, with consequences for the adaptive immune response [21,33,42,43].
Of note, transgenic mice overexpressing AnxA1 exclusively in T lymphocytes led to an
unexpected increase in anxiety, possibly due to an anxiogenic factor released by AnxA1
overexpressing T cells, which may contribute to increased susceptibility for mental disorders
in patients with autoimmune diseases [44].
2.1.1. AnxA1 and Progression of Chronic Diseases
In order to return local sites of inflammation to normal homeostasis, AnxA1 is now
considered a pro-resolving mediator that can counteract pro-inflammatory response. In fact,
administration of recombinant AnxA1 can delay or even regress the progression of chronic
diseases, such as cardiovascular disease [22,45–47] (Table 1b). For instance, in several
murine stroke models, AnxA1 administration mediated protective effects via FPR2 after
cerebral ischemia/reperfusion (I/R) injury [48] or more recently, after spontaneous intrac-
erebral hemorrhage [49], limiting further cerebral microvascular dysfunction and tissue
damage. In addition, binding of AnxA1-derived peptides to FPR2 on neutrophils was
demonstrated to regulate neutrophil-platelet aggregation, which contributed to attenuate
cerebral inflammation [50].
AnxA1 administration to low density lipoprotein receptor (LDLR)—deficient mice
that were fed a western-type diet attenuated progression of atherosclerotic plaques and was
accompanied by reduced FPR2-dependent neutrophil rolling and adhesion to endothelial
cells [51]. Conversely, enhanced atherosclerotic lesion formation and arterial myeloid cell
adhesion was observed in apolipoprotein E (apoE)−/− mice that lacked either AnxA1 or
FPR2. Administration of the AnxA1-derived peptide Ac2-26 ameliorated this phenotype in
the AnxA1 KO-mice but not in the FPR2 KO-mice, as judged by reduced atherosclerotic
lesion size, lessened macrophage accumulation in lesions and a decreased FPR2-dependent
recruitment of myeloid cells [32]. The protective capacity of AnxA1 was also documented
in a model of restenosis, examining mechanical wire injury in high-fat diet (HFD)—fed
AnxA1-deficient apoE−/− mice. In these animals, aggravated neointima development
due to the accumulation and proliferation of macrophages was observed, suggesting that
AnxA1 negatively regulates macrophage proliferation and its administration could serve
to prevent restenosis after vascular damage [52].
Relevant for cardiac repair after myocardial infarction (MI), AnxA1 deficiency in-
creased cardiac necrosis, inflammation, hypertrophy and fibrosis following MI and was
accompanied by an impaired macrophage phenotype [53]. The reduced cardiac function-
ality in Anxa1−/− mice after MI could be restored by AnxA1 administration, overcom-
ing compromised release of proangiogenic mediator vascular endothelial growth factor
(VEGF) from cardiac macrophages, and markedly improving neovascularization and car-
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diac repair [53]. AnxA1-based therapies improved cardiac outcomes after MI also in other
studies [54] (Table 1b).
2.1.2. AnxA1-Derived Peptides and Anti-Inflammatory Response
As mentioned above, administration of full length AnxA1 greatly advanced efforts to
explore the therapeutic potential of targeting FRP2 for anti-inflammatory strategies. Peptides
of the N-terminal AnxA1 region, the most widely used being the Ac2-26 peptide, also mimic
anti-inflammatory actions of full length AnxA1 [21–23,33,55,56]. The review articles listed
here summarize a substantial amount of work demonstrating that exogenous administration
of AnxA1 or Ac2-26 effectively limited or resolved inflammation in mouse models of stroke,
myocardial ischemia, non-alcoholic steatohepatitis, rheumatoid arthritis, multiple sclerosis,
colitis and asthma. AnxA1 deficiency was also detrimental in epithelial wound repair [11,57],
lung fibrosis [58], obesity and insulin resistance [59], skin grafting [60], bacterial infection [61,62],
as well as adrenal steroidogenesis in sepsis [63], or allergic conjunctivitis [64], and seems to
have regulatory functions in early pregnancy [65] (Table 1a,b).
Recently, resolving AnxA1 functions were documented in a murine model of cardiotoxin-
induced tibialis anterior injury. In this model, which is characterized by necrotic tissue damage
and extensive macrophage activity, extracellular AnxA1 was delivered to the injured tissue
through neutrophil recruitment and overexpressing macrophages, triggering FPR2-mediated
macrophage skewing towards a pro-reparative phenotype, dampening of inflammation and
ultimately, regeneration of skeletal muscle fibers [66]. It has yet to be determined how this
might relate to notexin-induced injury, which implicated AnxA1 deficiency to interfere with
cell–cell fusion during myofiber regeneration [67]. A protective function for AnxA1 was
also reported for mechanical injury-induced corneal scarring [68], acute colitis [69], and gout
inflammation [70] (Table 1c).
Ac2-26 also showed anti-inflammatory and neuroprotective effects in diseases related to
the central nervous system, such as pilocarpine-induced status epilepticus [71], kainic acid-
induced temporal lobe epilepsy [72], or cerebral inflammation in sepsis [73]. However, Ac2-26
administration in a mouse model of Alzheimer disease did not exert any beneficial effects [74],
possibly due to limitations in its ability to cross the blood–brain barrier (Table 1d).
2.2. AnxA1 and Diabetes
In the context of diabetic complications, initial studies reported that female Anxa1−/−
mice on the Balb/c background were more susceptible to weight gain and diet-induced
insulin resistance, without showing significant changes in inflammation [59] (Table 1e).
More recently, type 2 diabetic patients were found to exhibit increased AnxA1 plasma
levels, which correlated with fatty liver index and elevated plasma cholesterol [34]. In these
studies, a HFD in AnxA1−/− mice on the C57BL/6 background led to a more diabetic
phenotype. Treatment of HFD-fed wildtype mice with recombinant AnxA1 attenuated the
development of insulin resistance [34]. AnxA1 plasma levels in human type 1 diabetics
were similarly found to be elevated [75]. This coincided with a worse diabetic phenotype
and severe cardiac and renal dysfunction of streptozotocin (STZ)-induced type 1 diabetes
in AnxA1−/− mice. Strikingly, AnxA1 administration attenuated cardiac and renal com-
plications in diabetic AnxA1−/− animals, and was associated with reduced activity of
FPR2 signaling pathways [75]. In other studies, AnxA1 deficiency worsened pathological
remodelling of the mesenteric vasculature in insulin-resistant, but not insulin-deficient
animals [76], suggesting that AnxA1-based therapies could provide benefits for reducing
vascular injury in diabetes. In support of this, a novel AnxA1-mimetic (compound 17b)
provided vasoprotective effects in STZ-induced diabetic mice through the upregulation of
vasodilating prostanoids [77].
Several other functions of AnxA1 may contribute to improve diabetic complications
(Table 1e). For instance, exogenous AnxA1 enhanced glucose-stimulated insulin secretion
of islet cells, which could be beneficial in islet transplantation strategies as a therapy for type
1 diabetes [47,78]. Furthermore, Ac2-26 application in diabetic wounds reduced neutrophil
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accumulation and facilitated M2 macrophage development, both anti-inflammatory and
pro-repair effects required for wound closure [79]. On the other hand, it should be noted
that when analyzing skin wound healing in AnxA1-deficient mice, wound inflammation,
closure and formation of granulation tissue were not altered, and AnxA1 was proposed to
possibly be dispensible for wound hemostasis and repair [80].
2.3. Nanotechnology-Based Approaches to Deliver AnxA1-Derived Peptides
As outlined above, the Ac2-26 peptide is the most widely used AnxA1-derived peptide
to resolve inflammation. However, this peptide not only binds FPR2, but also FPR1 [23],
and a novel peptide covering a larger region of the AnxA1 N-terminus (2-48) specifically
bound FPR2 and reduced neutrophil recruitment during dermal inflammation [81]. Ad-
ditionally, as oral delivery of peptides for therapeutic use are known to suffer from low
bioavailability and metabolic liability, efforts to develop a more efficient and/or targeted
delivery of AnxA1-derived peptides have been made (Table 1f). For example, Ac2-26
was packaged onto nanoparticles that target collagen type IV, which is highly enriched in
atherosclerotic plaque. Advanced atheroslerotic lesions from mice receiving these Ac2-26
peptide-containing nanoparticles showed reduced lesion instability in a FPR2-dependent
manner [82], indicating an efficient and localized delivery of the Ac2-26 peptide.
Similarly, delivery of oxidation-responsive and Ac2-26 containing nanoparticles to
the inflamed colons of mice enabled site-specific release of the pro-resolving AnxA1-
mimetic peptide for the treatment of inflammatory bowel disease [83]. Oral delivery of
these oxidation-labile Ac2-26 containing nanoparticles effectively reduced inflammation
in the gastrointestinal tract, and improved intestinal wound healing [83]. The fact that
neutrophil-derived microvesicles contain AnxA1, which bind to FPR2 and contribute to
resolve cartilage protection in arthritic mice [84], also support nano-based therapeutic
strategies as a promising tool to deliver AnxA1 or AnxA1-mimetic peptides.
Other approaches include the fusion of AnxA1-derived peptides with a cell-penetrating
peptide to protect against neuronal apoptosis after cerebral ischemia [85], or the grafting of
a small bioactive AnxA1 peptide into a stable cyclic peptide scaffold for the reduction of
inflammation in a mouse model for acute colitis [86]. Alternatively, the development of a
doxorubicin-DNA aptamer conjugate that specifically recognizes AnxA1 on the surface of
cancer cells significantly enhanced targeted therapy against tumours in vivo [87]. Likewise,
coupling anticancer drugs to a peptide that recognizes AnxA1 on the tumour vasculature
surface enabled drug delivery across the blood–brain barrier to suppress growth of brain
tumours [88]. Finally, one report described the utilization of a monoclonal AnxA1 antibody
to suppress the autoimmune syndrome associated with an abnormal AnxA1 expression
on activated B and T cells in a mouse model of systemic lupus erythematosus (SLE), thus
underscoring the need for a balanced expression of this immune modulator [89].
2.4. AnxA1 and Cancer
Over the last few years, a lot of studies have explored a variety of therapeutic roles for
AnxA1 in cancer (Table 1g). For instance, chemotherapeutic agents such as anthracyclines
and cyclophosphamide can trigger an anticancer immune response, with long-term bene-
ficial effects beyond the initial chemotherapy. The underlying mechanism appears to be
based on the release of AnxA1 from cancer cells upon chemotherapy. AnxA1 then binds
to FPR1 on dendritic cells, which phagocytose and kill malignant cells, but also present
tumour-associated antigens, which are then recognized and eliminated by cytotoxic T
lymphocytes [90,91]. In support of this model, anticancer immunity after chemotherapy
with anthracyclines was compromised in mice with tumours lacking AnxA1, or when the
dendritic host cells lacked FPR1. This regulatory circuit may be tumour-type specific and
relevant in breast, colorectal, lung, and kidney, but not gastric cancers. Other limitations
to boost anticancer immunity in cancer patients via AnxA1 administration include the
high prevalence of a loss-of-function FPR1 allele common in all ethnic groups, which is
Int. J. Mol. Sci. 2021, 22, 3439 7 of 67
associated with poor prognosis, at least in breast cancer patients, after anthracycline-based
chemotherapy [90,92].
In contrast, scenarios driven by the binding of AnxA1 to FPRs have associated high
AnxA1 levels with poor patient survival and progression in metastatic and triple-negative
breast cancers (TNBC) [93]. Along these lines, AnxA1-deficient mice displayed reduced
breast cancer growth and enhanced survival, and it was proposed that AnxA1 binding
to FPR2 on macrophages, influencing their polarization and infiltration of solid tumours,
would be the underlying cause for enhanced tumour progression [94]. Alternatively,
increased binding of AnxA1 released from cancer cells to FPR2 on regulatory T cells may
impede anti-tumour immune responses [95]. Adding further complexity, secretion of
AnxA1 from TNBC cells might induce autocrine signalling via FPR1 to further increase
breast cancer cell aggressiveness and survival and could be blocked with cyclosporin A,
a FPR1 inhibitor [96].
The de-regulated signaling pathways in cancers triggered by extra- or intracellular
AnxA1 activities have yet to be fully elucidated [90–96]. Phosphoproteomics from AnxA1-
deficient mammary gland epithelial cells identified up- and downregulation of several
signaling pathways that modulate cell motility and could contribute to breast cancer initia-
tion [97]. Mechanistically, AnxA1 was shown to control epidermal growth factor receptor
(EGFR) receptor signaling and trafficking [98], which is probably modified through AnxA1
phosphorylation [99]. In pancreatic cancer, AnxA1 depletion conferred a less aggressive
phenotype and reduced liver metastasis independent of FPR pathways [100]. In a mouse
model for multiple myeloma, AnxA1 depletion improved bortezomib treatment [101],
but in nasopharyngeal carcinoma xenografts, loss of AnxA1 enhanced radiotherapy resis-
tance [102] (Table 1g).
2.5. Intracellular AnxA1 Activities
Besides the AnxA1/FPR axis, the AnxA1 KO-strain also revealed intracellular AnxA1
activities to modulate inflammation and other disease-related activities (Table 1h). For in-
stance, Anxa1−/− macrophages displayed an altered activity of signaling pathways and the
NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome, both affect-
ing inflammatory cytokine production, such as interferon-β and tumour necrosis factor
α (TNFα), but also release of lipid mediators [103–106]. Defects in the secretory pathway
of mesenchymal stromal cells from the AnxA1 KO-mice might explain the inability of the
secretome from these cells to stimulate glucose-induced insulin secretion of pancreatic β
cells [47,78].
In addition, nuclear translocation of AnxA1 [107], as well as AnxA1 affecting tran-
scriptional activation, mRNA transport and stability has been described [103,104]. In-
tracellular AnxA1 activities may also explain the upregulation of cyclooxygenase (COX)
and cytoplasmic phospholipase A2 (cPLA2) observed in Anxa1−/− fibroblasts, probably
driving enhanced and glucocorticoid-insensitive eicosanoid production in the Anxa1−/−
animals [24,108].
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Table 1. Phenotypes observed in AnxA1 in vivo models.
(a) AnxA1 and Acute/Chronic Inflammation




sclerosis, colitis, asthma, lung
fibrosis, bacterial infection, sepsis,
allergic conjunctivitis, gout
inflammation
AnxA1 KO-mice; FPR KO-models;
Administration of recombinant




activation of innate immune
response: neutrophil and monocyte
recruitment, clearance of apoptotic
cells, mast cell activation, reduced
inflammatory cytokines
AnxA1 binds to FPR2: downstream






(b) AnxA1 and Cardiovascular Disease
Stroke
I/R injury or intracerebral
hemorrage; Administration of




Delayed or regressed progression of
tissue damage
AnxA1/FPR2 and downstream




recombinant AnxA1 or Ac2-26
Reduced lesion size and
macrophage accumulation
AnxA1/FPR2 and downstream
effectors [32,51] reviewed in [22,23,45]











(c) AnxA1 and Tissue/Membrane Repair
Muscle injury Cardiotoxin-induced tibialisanterior injury in WT mice
Less inflammation; Restored muscle
repair
AnxA1 delivery via neutrophil
recruitment [66]
Muscle injury Notexin-induced injury in AnxA1KO-mice
Normal myofiber repair; Reduced
myofiber regeneration Cell–cell fusion [67]
Muscle injury Myofibers of ANO5 KO-mice Reduced AnxA1 accumulation atinjury site for cap formation Membrane resealing [113]
Skin grafting Ac2-26 administration in WT mice Improved skin transplantation andangiogenesis
AnxA1/FPR2 and downstream
effectors [60]
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Table 1. Cont.
Disease Model Phenotype Mechanism Ref
Mechanical injury-induced corneal
scarring Ac2-26 administration in WT mice




Intestinal wound repair AnxA1 KO-mice; Rescue withAnxA1 administration
Defects in intestinal mucosal wound
repair and epithelial cell migration
AnxA1/FPR2 and downstream
effectors [57]




AnxA1 dispensible in wound
closure? [80]



















Alzheimer’s disease Ac2-26 administration inAlzheimer’s mouse model No improvement
Ac2-26 not crossing blood–brain
barrier? [74]
(e) AnxA1 and Diabetes
Type 2 diabetes HFD-induced insulin resistance inAnxA1 KO-mice
Females more susceptible to





HFD-induced insulin resistance in
AnxA1 KO-mice; Ac2-26
administration in HFD-fed WT mice
More diabetic phenotype in AnxA1








Reduced cardiac and renal defects Reduced FPR2 signaling [75]
Type 1 and Type 2 diabetes STZ-treated and HFD-fed AnxA1KO-mice
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Table 1. Cont.
Disease Model Phenotype Mechanism Ref





Type 1 diabetes Transplantation ofAnxA1-pretreated islets in STZ-mice
Restoration of glucose-stimulated




wound healing in diabetic db/db
mice
Ac2-26 induced anti-inflammatory
and pro-repair effects AnxA1/FPR2 [79]
(f) Nano-Based Delivery Approaches of AnxA1 Peptides
Atherosclerosis Ac2-26 on nanoparticles targetingcollagen IV in plaque
Localized Ac2-26 delivery; Reduced
lesion instability AnxA1/FPR2 [82]
Bowel disease
Oxidation-labile Ac2-26 containing






Arthritis AnxA1-containing microvesiclesfrom neutrophils
Resolving of cartilage protection in
arthritic mice AnxA1/FPR2 [84]
Cerebral ischemia Fusion of AnxA1 withcell-penetrating peptide
Protection against neuronal
apoptosis Anti-apoptotic signaling? [85]
Acute colitis Grafting of small AnxA1 peptideinto stable cyclic peptide scaffold Reduced inflammation AnxA1/FPR2 [86]
Breast cancer Doxorubicin-DNA aptamerconjugate treatment of 4T1 tumours
Enhanced efficacy of targeted cancer
therapy
Drug conjugate binds AnxA1 on
cancer cell surface [87]
Brain cancer
Peptide-mediated anticancer drug
delivery (SN38) to B16 and C6 brain
tumours




barrier and targets tumour
vasculature via AnxA1
[88]






autoreactive T and B cells
[89]
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Table 1. Cont.
Disease Model Phenotype Mechanism Ref
(g) AnxA1 and Cancer
Fibrosarcoma, Non-small cell lung cancer
(NSCLC)
AnxA1-depleted MCA205 and TC-1
xenografts
Anticancer immune response after
chemotherapy AnxA1/FPR1 [90–92]
Triple-negative breast cancer (TNBC) 4T1 tumours in AnxA1 KO-mice Reduced cancer growth and macrophageinfiltration of tumours AnxA1/FPR2 [94]
Triple-negative breast cancer (TNBC) Treatment of 4T1 tumours with AnxA1antagonist
AnxA1 binding to FPR2 impedes anti-tumour
immune response AnxA1/FPR2 [95]
Breast cancer MDA-MB-231 xenografts Blocking AnxA1 binding to FPR1 reducestumour growth/aggressiveness AnxA1/FPR1 [96]
Breast cancer Mammary gland epithelial cells derived fromANXA1 KO-mice
Up-/downregulation of signaling pathways
in cell motility and cancer initiation AnxA1/FPR2? [97]
Pancreatic cancer AnxA1-depleted, orthotopic MIA PaCa-2xenografts Less aggressive, reduced liver metastasis AnxA1 pathways independent of FPRs [100]
Multiple myeloma AnxA1-depleted NCI-H929 tumours Improved bortezomib treatment [101]
Nasopharyngeal carcinoma AnxA1-depleted CNE2 xenografts Elevated radiotherapy resistance [102]
(h) AnxA1 and Intracellular Activities in Disease
Inflammation Macrophages from AnxA1 KO-mice Inflammatory cytokine production (IFN-β,TNFα), lipid mediators
Signaling pathways and NLRP3
inflammasome [103–106]
Inflammation Macrophages from AnxA1 KO-mice Inflammatory cytokine production (IFN-β,TNFα), lipid mediators
Nuclear AnxA1 translocation; transcription,
mRNA transport and stability [103,104]
Prostanoids Anxa1−/− fibroblasts COX and cPLA2 upregulation Glucocorticoid-independent [24,108]
Membrane transport: Exocytosis AnxA1−/− mesenchymal stroma cells Secretrome unable to stimulate insulinsecretion from pancreatic b-cells Exocytic membrane transport [47,78]
Membrane transport: Late
endosomes/lysosomes Anxa1
−/− fibroblasts Biogenesis of internal vesicles inmultivesicular bodies (MVBs) Inward vesiculation [109]
Membrane transport: Membrane contact sites
(MCS) Anxa1
−/− fibroblasts EGFR trafficking and cholesterol transfer Establishment of ER/endosome contact sites [110]
Membrane transport: Influenza infection AnxA1 KO-mice Reduced influenza infection Reduced uptake and exit from MVBs [111]
Membrane transport: Influenza infection Influenza infection of lung cells from WTmice after AnxA1 administration AnxA1 protects against viral infection AnxA1/FPR2 [112]
Abbreviations: Akt, protein kinase B; ANO5, Anoctamin 5; Anx, annexin; ApoE, apolipoprotein E; COX, cyclooxygenase; cPLA2, cytoplasmic phospholipase A2; EGFR, epidermal growth factor receptor; ER,
endoplasmic reticulum; FPR, formylated peptide receptor; I/R, ischemia/reperfusion; HFD, high-fat diet; IFN-β, interferon-β; JNK, janus kinase; KO, knockout; LDLR, low density lipoprotein receptor; MAPK,
mitogen-activated protein kinase; MCS, membrane contact sites; MI, myocardial infarction; miR, micro RNA; MVBs, multivesicular bodies; SLE, systemic lupus erythematosus; STZ, streptozotocin; TNFα, tumor
necrosis factor α; WT wildtype.
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Anxa1−/− fibroblasts also revealed the critical role of AnxA1 in the biogenesis of a
subpopulation of internal vesicles in multivesicular bodies (MVBs) [109]. In these studies,
AnxA1 was transported on to intraluminal MVB vesicles containing EGFR and was tyrosine-
phosphorylated upon EGFR activation. EGF-stimulated inward vesiculation was abolished
in Anxa1−/− fibroblasts, whereas basal inward vesiculation remained intact. Hence, physical
association and tyrosine phosphorylation of AnxA1 for EGF-stimulated and EGFR-containing
intraluminal vesicle formation within MVBs appears critical [109]. In addition, AnxA1
contributes to the establishment of membrane contact sites, which is likely relevant for
trafficking of receptors and transfer of ions and lipids such as cholesterol, between endosomal
and other compartments [110]. Additionally, Anxa1−/− mice are partially protected against
influenza A virus infection, involving reduced uptake and exit of internalized virus from
late endosomes/MVBs [111]. Yet, this protective effect of AnxA1 against viral infection
also requires the AnxA1/FPR2 signaling axis to increase alveolar macrophages, which are
decisive factors in the host defence against pathogens [112] (Table 1h).
3. AnxA2
In mice, AnxA2 is highly expressed in the lung, pancreas, colon, ileum and adrenal
tissues, while low AnxA2 levels are found in spleen, testis, kidney and liver [114]. In endo-
and epithelial cells, monocytes, macrophages, and many other cell types, AnxA2 regulates
microdomain formation and membrane repair at the plasma membrane, trafficking along
endo- and exocytic pathways, as well as RNA export from the nucleus [115,116]. Multi-
ple membrane-related AnxA2 activities involve interactions with the actin cytoskeleton
and phosphatidylinositol-4,5-bisphosphate, contributing to cell growth, differentiation,
apoptosis and migration [1,5,6,116].
Notably, AnxA2 forms a heterotetramer with p11 (S100A10), a member of the S100
protein family, and upon Src kinase-mediated phosphorylation of AnxA2 at tyrosine 23,
the intracellular AnxA2/p11 complex is translocated to the outer membrane leaflet. At the
cell surface, the heterotetrameric AnxA2/p11 complex acts as a scaffold that modulates
cell surface presentation of receptors and ion channels [117,118]. Indeed, the critical role of
the AnxA2/p11 complex for the cell surface presentation of serotonine receptors has been
validated in AnxA1-, p11-KO and other mouse models of depression [115,119,120].
3.1. AnxA2 and Vascular Homeostasis and Angiogenesis
On endothelial cells, extracellular AnxA2/p11 serves as a docking site for plasminogen
and tissue plasminogen activator (tPA), which promote plasmin generation and vascu-
lar fibrinolysis. The AnxA2/p11-mediated plasminogen activation has been extensively
discussed and we recommend several reviews for further reading [115,116,119–121].
AnxA2-deficient mice [122] (Table 2a) provided the first in vivo evidence that AnxA2
mediates fibrin clearance, as the AnxA2−/− mice showed substantial deposition of fibrin
and after induction of acute carotic artery thrombosis, displayed increased thrombosis.
Mechanistically, Src kinase and protein kinase C (PKC) were required for AnxA2/p11
translocation to the cell surface in the carotid artery injury model [123]. Further sup-
porting a connected role for AnxA2 and p11 in fibrinolysis, de-regulated fibrinolysis was
also observed in the p11 KO-mice [124]. This coincides with reduced p11 levels in the
Anxa2−/− mice, most likely due to increased p11 ubiquitination and degradation in these
animals [125].
In other studies, Anxa2−/− mice revealed AnxA2-mediated functions in vascular
homeostasis and angiogenesis, such as the formation of new blood vessels [115,122,126].
In a mouse model for diet-induced hyperhomocysteinemia, which is implicated in throm-
botic and atherosclerotic disease, fibrin accumulation and defects in neoangiogenesis were
similar to those observed in the Anxa2−/− mice [127]. Interestingly, AnxA2 isolated from
mice fed a high methionine diet failed to bind tPA and activate plasminogen and could only
be restored upon administration of exogenous AnxA2 [127]. In ischemic cerebral disease,
recombinant AnxA2 amplified tPA-mediated thrombolysis to prevent stroke [128]. Yet, al-
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though inhibition of plasmin generation has therapeutic potential in atherosclerosis, AnxA2
deficiency in apoE−/− mice did not reduce lesion development [115]. The latter observation
is challenged by AnxA2 deficiency suppressing atherogenic integrin α5 signalling caused
by oscillary shear stress, which reduced the development of atherosclerosis in apoE−/−
mice at regions with disturbed blood flow [129]. Recently, recombinant AnxA2 ameliorated
fibrinolytic dysfunction in a mouse model lacking the exchange protein directly activated
by cAMP (EPAC), which is required for fibrinolysis on the surface of vascular endothelial
cells [130] (Table 2a).
3.1.1. AnxA2 and Pulmonary Vasculature
In the pulmonary vasculature, endothelial cells from Anxa2−/− mice display reduced
barrier function and develop pulmonary edema and neutrophil infiltration in the lung
parenchyma in response to alveolar hypoxia. Pulmonary vascular integrity does not
seem to require the AnxA1/p11 tetramer, but AnxA2 complex formation with vascular
endothelial cadherin and its tyrosine phosphatases, to prevent vascular leak during alveolar
hypoxia [131] (Table 2b). In addition, AnxA2 can contribute to lung injury and fibrosis
by augmenting factor Xa fibrogenic activity [132]. Interestingly, within the pulmonary
vasculature, AnxA2 has now been found responsible for the severe side effects caused by
bleomycin, a clinically potent anticancer drug for a large variety of cancers. Bleomycin
binds AnxA2, which impedes transcription factor EB mediated autophagy, leading to the
induction of pulmonary fibrosis. Underlying mechanism involve bleomycin-induced NF-
kappaB (NFκB) inflammatory pathways leading to AnxA2 secretion. Strikingly, these toxic
side effects can be overcome by an AnxA2 peptide inhibitor (TM601) or AnxA2 deficiency
in mice, alleviating bleomycin-induced pulmonary inflammation and fibrosis [132–134].
In addition, a critical in vivo function of AnxA2 in the secretory pathway affects pul-
monary function (Table 2b). Anxa2−/− displayed reduced exercise tolerance and impaired
lung tissue elasticity that resembles the phenotype of collagen VI (COL6) deficiency, which
anchors basement membranes to other collagen fibers [135]. Indeed, the Anxa2−/− lung
basement membrane lacked COL6, which accumulated and mislocalized in the Golgi
apparatus [135]. This phenotype of the Anxa2−/− mice correlated with the association
of AnxA2 with COL6, but also two SNARE (soluble NSF attachment protein receptor)
proteins, synaptosomal-associated protein 23 (SNAP23) and vesicle-associated membrane
protein 2 (VAMP2), in secretory vesicles from bronchial epithelial cells (Table 2b). This is in
line with previous reports identifying AnxA2 to regulate exocytosis via several SNAREs,
including SNAP23 and VAMP2 [136,137]. This secretory function of AnxA2 may extend to
other disorders associated with COL6 deficiency [135] or exocytic events driving cancer
progression [138–140].
3.1.2. Other AnxA2-Related Aspects in Vascular Homeostasis
Other AnxA2-related aspects in vascular homeostasis and angiogenesis include the
high AnxA2 antibody titers associated with thrombotic complications in cerebral venous
thrombosis [115,119,120] as well as the antiphospholipid syndrome [141,142]. AnxA2 up-
regulation also correlated with hyperfibrinolysis in acute promyelocytic leukemia [119,120].
Administration of recombinant AnxA2 increased neovascularization and inflammation in
mice with collagen-induced arthritis via binding to an AnxA2 receptor described previ-
ously [143] and subsequent activation of the Hedgehog pathway [144]. On the other hand,
lentiviral AnxA2 receptor overexpression suppressed neovascularization in the mouse aor-
tic ring and matrigel plug assays [145]. The role of AnxA2 in vascular homeostasis extends
to endothelial permeability and integrity at the blood–brain barrier after cerebrovascu-
lar injury, with AnxA2-deficient mice displaying increased inflammation and reduced
expression of cerebral endothelial junctional proteins [146,147]. For further reading of
AnxA2-related aspects in vascular homeostasis and angiogenesis we recommend several
excellent reviews [115,116,119–121,142] (Table 2c).
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3.2. AnxA2 and Lipid-Related Disorders
Several studies investigated AnxA2 in mouse models for lipid-related disorders (Table 2d).
Possibly relevant for hypercholesterolemic settings, AnxA2 or the AnxA2/p11 complex inhibited
proprotein convertase subtilisin/kexin-9 (PCSK9)-mediated LDLR downregulation, leading to ele-
vated LDLR levels at the cell surface [114,148]. Anxa2−/− mice displayed elevated LDL-cholesterol
and circulating PCSK9 levels, while LDLR levels were reduced in extrahepatic tissues. Vice versa,
adenoviral AnxA2 overexpression elevated hepatic LDLR levels in vivo [114]. The association of
LDL-cholesterol levels with Anxa2 gene variants [149] support modulation of AnxA2 levels as a
potential cholesterol-lowering strategy. Applicable for obesity and the metabolic syndrome, AnxA2
depletion attenuated obesity-induced insulin resistance through suppression of NFκB signaling [150].
Furthermore, in vascular endothelial cells of white adipose tissue (WAT), AnxA2 forms a complex
with prohibitin and the fatty acid transporter CD36. Anxa2−/− mice exhibited defective fatty acid
uptake by the WAT endothelium and adipocytes, making this regulatory circuit a new target for
metabolic intervention in obesity [151] (Table 2d).
3.3. AnxA2 and Cancer
A substantial number of studies in recent years examined AnxA2 in cancer growth
and progression in vivo, identifying diverse AnxA2 functions in tumourigenic settings
(Table 2e).
In mouse models for pancreatic ductal adenocarcinoma (PDAC), AnxA2 KO-animals
displayed a substantial reduction in PDAC tumour invasion and metastasis. Src-dependent
AnxA2 tyrosine 23 phosphorylation and cell surface translocation, as well as AnxA2
regulating the secretion and autocrine signaling of semaphorin 3D (SEMA3D) contribute
to PDAC invasion and metastasis [138]. The reduced SEMA3D secretion upon loss of
AnxA2 also lowered the incidence of perineural invasion and metastasis of orthotopic
pancreatic tumours in mice [152]. PDAC metastatic behaviour is strongly influenced by
stromal cells in the tumour microenvironment and pharmacological inhibition of signaling
events initiated by factors released from stroma cells, including hepatocyte growth factor,
insulin-like growth factor 1 or tenascin C, reduced AnxA2 phosphorylation and metastatic
potential of PDAC tumours [139,140,153]. In fact, stromal AnxA2 expression has potential
as a predictive biomarker for survival outcomes in PDAC [154]. The therapeutic potential
of targeting AnxA2 in PDAC was further emphasized with the recent development of
an AnxA2-targeting vaccine approach, which in combination with immune checkpoint
inhibitors, led to survival benefits in PDAC mouse models [155]. Additional evidence for
roles of AnxA2 in the tumour microenvironment came from the inoculation of prostate
cancer cells with bone marrow stromal cells from the AnxA2 KO-mice. This approach
revealed that AnxA2 binding to stromal-derived factor 1 strongly influenced recruitment,
growth and survival of prostate cancer cells in the bone marrow microenvironment [156]
(Table 2e).
Therapeutic Potential of AnxA2 in Cancer
Several animal studies proposed multiple roles for AnxA2 in brain cancers. In pediatric
neuroblastoma, AnxA2 depletion attenuated NFκB activity and enhanced anticancer drug
sensitivity, which improved chemotherapy in a xenograft model for neuroblastoma [157].
Likewise, AnxA2-mediated NFκB signaling contributed to tumourigenicity in xenograft
models for glioblastoma multiforma (GBM) [158], with AnxA2 depletion strongly inhibiting
GBM tumour growth and improving survival [159]. In the latter studies, AnxA2-mediated
phosphorylation of signal transducer and activator of transcription 3 (STAT3) increased
expression of microRNA miR155 to promote epithelial-to-mesenchymal transition (EMT)
in glioma [159]. Other downstream targets of the AnxA2-STAT3 axis to promote growth
and phenotypic transition in GBM include the oncostatin M receptor [160] and the cyclin
D1 pathway [161] (Table 2e).
In breast cancer, intra- and extracellular AnxA2 activities and locations, including exo-
somes [162], have become promising therapeutic targets. AnxA2 antibody-conjugated and
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curcumin-loaded nanoparticles effectively accumulated in tumours, providing sustained
release of curcumin with potential to reduce metastatic breast cancer progression [163].
A monoclonal AnxA2 antibody not only allowed monitoring EMT in breast and ovarian
cancers, but also provided antibody-dependent cell toxicity and efficient killing when
conjugated to cytotoxic drugs and expressed as a chimeric immunoglobulin G1 [164–166].
Other beneficial effects of AnxA2 antibodies include the inhibition of neoangiogenesis in
TNBC xenograft models, which involves reduced plasmin generation as well as loss of
AnxA2 tyrosine 23 phosphorylation [167,168]. The latter requires interaction with Src and
Rack1 kinases, and could be responsible for the acquirement of drug resistance in aggres-
sive breast cancers [169]. In support of this, AnxA2 depletion improved the suppressive
xenograft growth effect of Src kinase and VEGF inhibitors in esophageal cancers [170].
In fact, AnxA2 contributes to the development of resistance to cisplatin and tyrosine
kinase inhibitors targeting EGFR in non-small cell lung cancers [171,172]. Vice versa, disrup-
tion of AnxA2/p11 interaction with small molecule inhibitors or AnxA2 antibodies reduced
acute lymphoblastic leukemia proliferation and sensitized tumour cells to chemother-
apy [173].
Although data from p11 KO-mice often supports findings that AnxA2/p11-dependent
plasmin generation is involved in tumour progression [115,116,121], it should be noted that p11
has plenty of other tumourigenic functions that appear rather unrelated to AnxA2 [174,175].
It would also go beyond the scope of this review to discuss in detail cancer-related animal
studies that identified upstream regulators of AnxA2 expression or activity [176–178]. However,
other studies, for example in glioma, suggest that not only tetrameric, but also monomeric
AnxA2 might serve as a strategy to develop it as a vaccine adjuvant to increase anti-tumour
immunity [179] (Table 2e). Alternatively, a novel RNA nanoparticle harboring an AnxA2
aptamer was developed to target ovarian cancer for doxorubicin delivery [180]. Similary, a
DNA aptamer that binds AnxA2 on cancer cells could become a tool to diagnose and treat
multiple myeloma [181]. Along these lines, a cyclic octapeptide labeled with a near-infrared
dye selectively binding phosphorylated AnxA2, which is highly expressed in a wide range of
solid tumours, provides opportunity for tumour imaging and localized drug delivery [182].
Alternatively, treatment of tumour cells with a cytosol-targeting small peptide that binds to
intracellular AnxA2 showed a reduced capacity to colonize lungs in several mouse models [183]
(Table 2e).
3.4. AnxA2 and Infection
Several recent studies addressed roles for AnxA2 in response to bacterial and viral
infections, some of those identifying roles for AnxA2 in membrane organization and
endocytic transport (Table 2f). For instance, pathogen recognition and activation of innate
immunity in macrophages requires Toll-like receptor 4 (TLR4) activation at the plasma
membrane and on endosomes. Remarkably, in Anxa2−/− mice enhanced TLR4 signaling
and reduced TLR4 endocytosis was associated with an increased susceptibility to bacteria-
induced pulmonary inflammation [184].
During fungal infection (Cryptococcus) of macrophages, AnxA2 controls phagocytosis
and non-lytic exocytosis of the pathogen. Compromised fungal uptake, propagation
and release, together with an enhanced inflammatory response, probably explains that
Anxa2−/− mice died more rapidly than control animals after fungal infection [185].
In studies addressing autophagy, vesicles isolated from dendritic cells of Anxa2−/−
mice contained reduced amounts of phosphatidylserine (PS) and phosphatidylinositides.
These vesicles generate phagosomes for encapsulation of organelles and biomolecules,
followed by their degradation in endo-/lysosomes. Phagosome biogenesis and maturation
in dendritic cells from the Anxa2−/− mice was strongly reduced [186]. Autophagy can also
serve as a defence mechanisms against bacterial infection, and was de-regulated in a mouse
infection model using Anxa2−/− animals [187].
In a mouse model for Alzheimer’s disease, AnxA2 interacts with phosphorylated
presenilin 1 and the SNARE protein VAMP8, the latter binding to the autophagosomal
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SNARE syntaxin 17. This ultimately facilitates fusion of autophagosomes with lysosomes,
thereby increasing b-amyloid degradation, which has therapeutic potential for Alzheimer’s
disease [188].
Tick saliva contains effector molecules that inhibit host immunity and facilitate
pathogen transmission. One of the tick proteins, sialostatin L2, binds AnxA2, which
then impairs the formation of the NLRC4 inflammasome, responsible for the matura-
tion and secretion of pro-inflammatory cytokines. Accordingly, AnxA2-deficient mice
were more succeptible to Anaplasma phagocytophilum infection, leading to splenomegaly,
thrombo- and monocytopenia [189]. On the other hand, during the pathophysiology of
sepsis, Anxa2−/− mice showed increased production of pro-inflammatory IL-17 and reac-
tive oxygen species, increased neutrophil infiltration, but reduced bacterial clearance and
animal survival [190]. While these studies rather implicate intracellular AnxA2 functions,
during the adhesion and invasion of uropathogenic Escherichia coli to bladder epithelial
cells, AnxA2 was identified as the receptor of the bacterial protein YadC, which participates
in binding to bladder epithelial cells [191]. Inhibition of AnxA2 using the Ca2+-chelator
BAPTA-AM or compound A-05, which inhibits the AnxA2/p11 complex [192], attenuated
E.coli infection in vivo [191]. Likewise, AnxA2 on the surface of vascular endothelial cells
served as a docking site for Rickettsia, with AnxA2 deficiency blocking Rickettsia adherence
to the luminal surface of blood vessels in vivo [193] (Table 2f).
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Table 2. Phenotypes observed in AnxA2 in vivo models.
(a) AnxA2 and Vascular Homeostasis and Angiogenesis
Disease Model Phenotype Mechanism Ref
Acute carotic artery injury AnxA2 KO-mice Deposition of fibrin; Increasedthrombosis
Src- and PKC-dependent
AnxA2/p11-translocation and




Diabetic retinopath AnxA2 KO-mice
Compromised neoangiogenesis in
matrigel implant, corneal pocket
and oxygen-induced retinopathy
AnxA2/p11-mediated plasmin
generation and vascular fibrinolysis [114,121,126]
Stroke AnxA2 administration in rat modelof ischemic stroke Prevention of stroke
Exogenous AnxA2 amplified
tPA-mediated thrombolysis [128]
Atherosclerosis AnxA2/ApoE Double-KO mice No changes in lesion development [115]
Atherosclerosis AnxA2/ApoE Double-KO mice
Reduced development of
atherosclerosis in regions with
disturbed flood flow
Suppressed integrin α5 signaling
caused by oscillary shear stress [129]
Vascular fibrinolysis AnxA2 administration in EPACKO-mice Improved fibrinolytic function
AnxA2/p11-mediated plasmin
generation and vascular fibrinolysis [130]
(b) AnxA2 and Pulmonary Vasculature
Disease Model Phenotype Mechanism Ref
Alveolar hypoxia AnxA2 KO-mice
Reduced endothelial cell barrier
function; Pulmonary endema,
neutrophil infiltration in lung
parenchyma
AnxA2 complex with endothelial
cadherin and tyrosine phosphatases [131]
Lung injury, idiopathic pulmonary
fibrosis (IPF) AnxA2 KO-mice Reduced lung injury and IPF




AnxA2 KO-mice; Administration of
AnxA2 inhibitor (TM601) or AnxA2
antibodies
Reduced lung inflammation and
fibrosis
AnxA2 binds bleomycin. This
impedes TFEB-mediated autophagy
to cause pulmonary fibrosis
[132–134]
Congenital muscular dystrophies
and respiratory dysfunction AnxA2 KO-mice
Similar to COL6 deficiency: reduced
exercise tolerance and impaired
lung tissue elasticity
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Table 2. Cont.
(c) AnxA2 and Other Aspects of Vascular Homeostasis
Disease Model Phenotype Mechanism Ref
Cerebral venous thrombosis,
antiphospholipid syndrome
AnxA2 KO-mice; Administration of
recombinant AnxA2; patient data
Elevated AnxA2 autoantibodies
lead to thrombotic complications AnxA2/p11 [115,119,120,141,142]
Collagen-induced arthritis Administration of recombinantAnxA2
Increased neovascularization and
inflammation
AnxA2 binding to AnxA2 receptor
induces Hedgehog signaling [143,144]
Neovascular-related diseases
AnxA2 receptor overexpression in












AnxA2/p11? AnxA2 receptor? [146,147]
(d) AnxA2 and Lipid Disorders
Disease Model Phenotype Mechanism Ref
Hypercholesterolemia, CVD AnxA2 KO-mice; hepatic AnxA2overexpression; patient data
Elevated LDL-cholesterol and
PCSK9 levels






AnxA2 depletion in obesity-induced
insulin resistance Attenuated insulin resistance Suppression of NFκB signaling [150]
Obesity AnxA2 KO-mice Reduced fatty acid uptake in WAT AnxA2 complex with prohibitin andCD36 [151]
(e) AnxA2 and Cancer
Disease Model Phenotype Mechanism Ref
Pancreatic ductal adenocarcinoma
(PDAC)
AnxA2-KO crossed with PDAC
mouse model
Reduced PDAC invasion and
metastasis





PDAC Stroma signaling inhibitors inPDAC mouse models Reduced PDAC metastasis
Suppression of AnxA2
phosphorylation [139,140,153]
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Table 2. Cont.
PDAC Administration of AnxA2-targetingvaccine in PDAC mouse models Improved survival
Inhibition of AnxA2-mediated
oncogenic events [155]
Bone marrow metastasis AnxA2 depleted bone marrow cellsin mice with prostate tumours
Reduced recruitment, growth,
survival of prostate cancer cells in
bone marrow
AnxA2 binding to CXCL12 and
stromal-derived factor 1 [156]
Brain cancer
AnxA2 depletion in SK-N-BE(2)
xenografts (pediatric
neuroblastoma)
Improved chemotherapy Attenuated NFκB activity [157]
Brain cancer AnxA2 depletion in U87 xenografts(glioblastoma multiforma, GBM)
Reduced GBM growth and
improved survival
AnxA2-mediated STAT3 activation
promotes EMT transition via




Brain and lung metastasis of
MDA-MB-231, MDA-MB-831, and







Breast cancer AnxA2 antibody conjugated andcurcumin-loaded nanoparticles




Breast and ovarian cancers
Administration of AnxA2 antibody
conjugated to IgG or anticancer
drugs to IGROV1 xenografts
Antibody-dependent cell toxicity
and killing Targeted delivery to tumours [164–166]
TNBC Administration of AnxA2antibodies to TNBC xenografts Inhibition of neoangiogenesis
Reduced AnxA2 phosphorylation
and plasmin generation [167–169]
Esophageal cancers AnxA2 depletion in KYSE30xenografts
Improved anti-cancer efficacy of Src
and VEGF inhibitors
Loss of AnxA2 phosphorylation and
Myc-Hif1α-VEGF activation [170]
Non-small cell lung cancer (NSCLC) AnxA2 depletion incisplatin-resistant A549 xenografts Increased cisplatin sensitivity
AnxA2-mediated JNK/c-Jun
signaling reduces p53 activity [171]
Lung cancer (NSCLC)
AnxA2 depletion in HCC827 and
PC9
xenografts
ANXA2 depletion reversed EMT
phenotype and gefitinib resistance
CAFs secrete HGF and IGF-1, which






inhibitor or AnxA2 antibodies to
ALL mouse models
Reduced metastasis and improved
chemotherapy
Blocked ability of AnxA2/p11 to
promote adhesion, homing and
engraftment of ALL cells
[173]





to GL261 tumour mouse models
Improved anti-tumour immunity
Monomeric AnxA2 binds to
Toll-like receptor 2 to promote CD8+




nanoparticle with AnxA2 aptamer
to SKOV3 xenografts
Improved doxorubicin delivery and
efficacy
Targeting AnxA2 on ovarian cancer
cells for drug delivery [180]
Multiple myeloma (MM)
Administration of DNA aptamer
targeting AnxA2 on ARP-1
xenografts
Blocked MM adhesion and
proliferation
Targeting AnxA2 on cancer cell
surface [181]
Solid tumours
Administration of cyclic octapeptide
targeting p-AnxA2 on 4T1 breast,
HT1080 fibrosarcoma and BxPC-3
pancreatic tumours
Effective tumour imaging and
monitoring if drug delivery
Elevated levels of phosphorylated
AnxA2 in tumour tissues [182]
Lung metastasis
Mouse lung colonization models
(KRIB, B16F10, LLC). Pre-treatment
with peptide targeting intracellular
AnxA2
Reduced adhesion, migration and
capacity to colonize lungs
Blocked interaction of AnxA2 with
cytoskeleton [183]
(f) AnxA2 and Infection
Disease Model Phenotype Mechanism Ref
Bacteria-induced pulmonary
inflammation AnxA2 KO-mice
Increased susceptibility to bacterial
infection
Toll-like receptor 4 (TLR4)
trafficking defects causing enhanced
TLR4 signaling
[184]
Fungal infection AnxA2 KO-mice Enhanced inflammatory responseand death
Compromised fungal uptake,
propagation and release [185]
Macroautophagy AnxA2 KO-mice Reduced phagosome biogenesis andmaturation in denditric cells
AnxA2 recruits phosphoinositides
and PS to vesicular membranes,









increased superoxide release in the
lung
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Table 2. Cont.
Alzheimer’s disease Alzheimer mouse models AnxA2 is a therapeutic target inAlzheimer’s disease
AnxA2 binds phosphorylated preselenin-1 and
VAMP8 to enable fusion of autophagosomes with
lysosomes, which increases β-amyloid degradation
[188]
Acute febrile illness (anaplasmosis) AnxA2 KO-mice




AnxA2 binds sialostatin L2, which triggers
pro-inflammatory cytokine production [189]
Sepsis AnxA2 KO-mice Reduced bacterial clearance and survival Increased IL-17 and reactive oxygen speciesproduction [190]
Bladder infection
Administration of Ca2+ chelator or
AnxA2/p11 inhibitor to mice infected
with E.coli
Attenuated E. coli infection Loss of AnxA2 as the receptor of bacterial proteinYadC on bladder epithelial cells [191]
Rickettsia infection AnxA2 KO-mice Blocked Rickettsia adherence to luminalside of blood vessels
Loss of AnxA2 as the receptor of Rickettsia on
vascular endothelial cells [193]
(g) AnxA2 and Muscle Repair
Disease Model Phenotype Mechanism Ref
Dysferlinopathy AnxA2 KO-mice
Poor sarcolemma repair, progressive and
age-dependent decline in muscle
function, lack of adipogenic replacement
of myofibers
Similar to dysferlin deficiency but without chronic
inflammation; AnxA2 target for dysferlinopathy [194,195]
Limb girdle muscular dystrophy
(LGMD) 2B
AnxA2 administration in mouse LGMD
2B model Enhanced muscle loss [195]
(h) AnxA2 and Other Biological Activities
Disease Model Phenotype Mechanism Ref
Preeclampsia AnxA2 KO-mice Impaired embryo implantation andplacentation
Impaired decidualization of endometrial stromal
cells and uterine environment; AnxA2 acts as
adhesion molecule during implantation
[196,197]
Chronic pain (tissue damage, harmful
chemicals) AnxA2 KO-mice Enhanced TRPA1-dependent pain
AnxA2 is a ligand for TRPA1 responsible for ion
channel regulation [198]
Abbreviations: Akt, protein kinase B; ALL, acute lymphoblastic leukemia; ANO5, Anoctamin 5; Anx, annexin; ApoE, apolipoprotein E; COL6, collagen VI; CAFs, cancer associated fibroblasts; CVD, cardiovascular
disease; EMT, epithelial-to-mesenchymal transition; FPR, formylated peptide receptor; GBM, glioblastoma multiforme; IgG, immunoglobulin G; I/R, ischemia/reperfusion; HFD, high-fat diet; Hif-1a,
Hypoxia-inducible factor-1a; IL, interleukin; IPF, idiopathic pulmonary fibrosis; JNK, janus kinase; KLF2, kruppel-like factor 2; KO, knockout; LGMD, Limb girdle muscular dystrophy; LDLR, low density
lipoprotein receptor; MAPK, mitogen-activated protein kinase; MI, myocardial infarction; miR, micro RNA; mTOR, mechanistic target of rapamycin; NFκB, nuclear factor kappa B; PCSK9, proprotein convertase
subtilisin/kexin-9; PDAC, pancreatic ductal adenocarcinoma; PI3K, phosphoinositide-3-kinase; PKC, protein kinase C; PS, phosphatidylserine; SEMA3D, semaphoring 3D; SLE, systemic lupus erythematosus;
SNARE, soluble NSF attachment protein receptor; SAT3, signal transducer and activator of transcription 3; STZ, streptozotocin; TFEB, transcription factor EB; TLR4, Toll-like receptor 4; TNBC, triple-negative
breast cancer; tPA, tissue plasminogen activator; TRPA1, transient receptor potential ion channel A1; ULK, Unc-51 like autophagy activating kinase; VEGF, vascular endothelial growth factor; WT wildtype.
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3.5. AnxA2 and Muscle Repair
Two recent studies linked AnxA2 with myofiber repair and inflammation in mus-
cle [194,195] (Table 2g). Muscle repair after sarcolemmal damage requires dysferlin, and
similar to dysferlin deficiency, lack of AnxA2 in myofibers was associated with poor sar-
colemma repair and a progressive age-dependent decline in muscle function. Yet, AnxA2
deficiency did not cause chronic inflammation that is commonly observed upon loss of
dysferlin. Moreover, AnxA2-depleted mice showed extensive myofiber regeneration after
laser injury, but not degeneration or adipogenic replacement, making AnxA2 a novel target
to treat dysferlinopathy [194]. Indeed, lack of AnxA2 prevented adipogenic replacement of
myofibers, while exogenous AnxA2 enhanced muscle loss in mouse models for limb girdle
muscular dystrophy 2B, which is caused by dysferlin mutations [195].
3.6. Other AnxA2-Related Biological Activities
Although the underlying mechanism remain to be fully clarified, roles for AnxA2 in
actin polymerization and secretion might be involved in preeclampsia, a pregnancy-specific
disorder, as AnxA2 deficiency impaired decidualization of endometrial stromal cells and
the uterine microenvironment that promotes embryo implantation and placentation [196].
Alternatively, AnxA2 might act as an adhesion molecule at the endometrial epithelium
during embryo implantation [197] (Table 2h).
Finally, in vivo evidence that links AnxA2 with ion channel regulation [1,2] includes
AnxA2 being a ligand for the transient receptor potential ion channel A1 (TRPA1), which is
responsible for the detection of harmful chemicals, tissue damage and chronic pain.
Anxa2−/− mice displayed increased surface levels of TRPA1 on sensory neurons, which
correlated with enhanced TRPA1-dependent pain in these animals [198].
4. AnxA3
AnxA3 is found in many cell types and preferentially expressed in the spleen, lung
and reproductive organs with roles in membrane transport, ion transport, cytoskeletal
interactions, cell signaling, inflammatory responses, endothelial cell migration, adipocyte
differentiation, and vascular development [199–204].
4.1. AnxA3 and Cancer
Several studies examined AnxA3 loss- or gain-of-function in xenograft models, impli-
cating AnxA3 depletion as a tool to improve anticancer drug sensitivity (Table 3). For in-
stance, downregulated AnxA3 levels improved cisplatin sensitivity in ovarian cancer [205].
Similarly, AnxA3 silencing in MDA-MB-231 breast cancer cells strongly reduced lung
metastasis with increased sensitivity towards doxorubicin, possibly through NFκB inhi-
bition [200]. Others reported AnxA3 depletion in MDA-MB-231 cells to strongly reduce
xenograft growth and angiogenesis in the tumour microenvironment [206]. AnxA3 silenc-
ing using miR382, which was accompanied by phosphoinositide-3-kinase/(PI3K)/protein
kinase B (Akt) downregulation, reduced EMT and lymph node metastasis of pancreatic
cancer cells [207]. In A549 lung adenocarcinoma cells, AnxA3 deficiency reduced MAPK
signaling and decreased expression of metalloproteases and E-/N-cadherin, thereby re-
ducing xenograft growth, as well as metastasis to lung, liver and brain after tail vein
injection [208]. In lung cancer, cancer associated fibroblasts (CAFs) increased AnxA3 lev-
els in the neighbouring cancer cells, which correlated with increased cisplatin resistance.
In contrast, AnxA3 knockdown in this model increased cisplatin sensitivity, an observation
that may add to overcome drug resistance in lung cancer patients [209]. In other stud-
ies, elevated AnxA3 levels suppressed PKCδ/p38 MAPK-dependent onset of apoptosis
and autophagy [210] and might be a target for immunotherapy in hepatocellular carci-
noma [201]. Along these lines, AnxA3 monoclonal antibodies sensitized hepatocellular
carcinoma to the tyrosine kinase inhibitor sorafenib [210]. Finally, AnxA3 depletion in
microglia alleviated bone cancer-induced pain through inhibition of hypoxia-inducible
factor-1a/VEGF-dependent signaling [211] (Table 3).
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Table 3. Phenotypes observed in AnxA3 in vivo models.







































































































Abbreviations: Akt, protein kinase B; Anx, annexin; BCP, bone cancer-induced pain; CAFs, cancer associated
fibroblasts; Hif-1α, Hypoxia-inducible factor-1α; JNK, janus kinase; KO, knockout; MAPK, mitogen-activated
protein kinase; miR, micro RNA; NFκB, nuclear factor kappa B; PI3K, phosphoinositide-3-kinase; PKC, protein
kinase C; VEGF, vascular endothelial growth factor.
5. AnxA4
AnxA4 is expressed prominently in secretory epithelia of the lung, intestine, stom-
ach and kidney [212]. Out of the three AnxA4 mRNAs (AnxA4a-c), AnxA4a is broadly
distributed, while AnxA4b and AnxA4c are only found in the digestive track and soli-
tary chemosensory cells, respectively [213]. After Ca2+ elevation, AnxA4 translocates to
the plasma membrane or the nuclear membrane, but also has the ability to oligomerize
and participate in Ca2+-dependent aggregation of vesicles or modulate the mobility of
membrane-associated proteins [214–216]. While the latter may implicate a role in repair
mechanisms, administration of pharmacological AnxA4 concentrations caused bleeding in
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skin wound repair [80]. AnxA4a-deficient urothelium did not reveal alterations in bladder
function [217], but airway epithelial cell migration was impaired upon AnxA4 depletion,
with consequences for airway branching morphogenesis during lung development [218].
In cardiomyocytes from adult AnxA4 KO-mice, β-adrenoreceptor (β-AR) agonists
more potently increased cAMP levels, which coincided with enhanced cardiac contraction
force in the heart [219]. The underlying cause involves the inhibitory action of AnxA4
on adenylyl cyclase 5, which controls conversion of ATP into cAMP, an activity that was
recently mapped to the N-terminus of AnxA4 [220] (Table 4).
Table 4. Phenotypes observed in AnxA4 in vivo models.
Tissue/Disease Model Phenotype Mechanism Ref






































































































Abbreviations: Anx, annexin; β-AR, β-Adrenoreceptor; Ca2+, calcium; cAMP, cyclic adenosine monophosphate;
ERK1/2, extracellular signal-regulated protein kinase 1/2; GBC, gallbladder carcinoma; JNK, Janus kinase; KO,
knockout; NFκB, nuclear factor kappa B; STAT3, signal transducer and activator of transcription 3.
5.1. AnxA4 in Cancer
AnxA4 is upregulated in various epithelial cancers, and AnxA4 knockdown reduced
xenograft growth of gallbladder cancer cells, possibly by downregulating oncogenic NFκB
signaling pathways [221]. Likewise, AnxA4 depletion decelerated the in vivo growth of
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tumours derived from basal-like breast cancer cell lines. In this model, AnxA4 interacted
with another annexin, AnxA1, to activate Janus kinase-STAT3 signaling [222].
Several studies examined AnxA4 in the context of anticancer drug resistance (Table 4).
In xenografts from endometrial carcinoma cells, AnxA4 overexpression conferred cisplatin
resistance, possibly by interacting with the copper transporter ATP7A, and promoting its
ability to efflux platinum drugs [223]. Vice versa, AnxA4 depletion increased sensitivity to
platinum-based drugs in vivo in a Ca2+-dependent manner [224]. Finally, chemoresistance
of lung cancer cells correlated with AnxA4 translocation to the plasma membrane. Blocking
AnxA4 translocation with a heptapeptide derived from the tumour suppressor FHIT
restored the chemosensitivity to paclitaxel [225].
6. AnxA5
AnxA5 is the most abundant annexin in almost all cells and tissues, except neurons [1,226]
(Table 5). In cells, AnxA5 is associated with the plasma membrane, nucleus, Golgi, endo-
plasmic reticulum, late endosomes/lysosomes, phagosomes, and mitochondria, often in a
Ca2+-dependent manner and linked to the regulation of membrane transport, Ca2+ signaling,
ion channels, Ca2+-influx, cell cycle, apoptosis and phagocytosis [227–233]. In addition, sub-
stantial amounts of AnxA5 are found extracellularly, and due to its strong binding affinity
towards PS in the outer leaflet of the plasma membrane, AnxA5 is now a widely used diag-
nostic tool to detect apoptotic cells in various disease settings [226] (Table 5b–e and details
below).
6.1. AnxA5 and Differentiation
Given the abundant AnxA5 levels in many tissues, several studies utilized the AnxA5
KO-mice to address possible roles in development. Indeed, the targeted disruption and
replacement with an Anxa5-lacZ fusion gene enabled detailed AnxA5 expression analysis
during embryonal mouse development, identifying Anxa5-lacZ expression specifically
in populations of perivascular cells of non-skeletal mouse tissues, with critical roles in
initial steps of angiogenesis differentiation and maturation of endothelial cells by per-
icytes [234,235]. However, and despite high AnxA5 levels in cartilaginous tissues and
bone, the AnxA5 KO-mouse lacked any defects in the calcification process during skeletal
development [236] (Table 5). This led to speculations that other annexins, in particular
AnxA6, could compensate for AnxA5 deficiency [236,237]. Yet, double KO-mice deficient of
AnxA5 and AnxA6 (Anxa5−/−/Anxa6−/−) or mice lacking both AnxA5 and AnxA6 as well
as collagen X showed normal skeletal development [238,239], indicating these annexins not
being essential for the calcification of the growth plate cartilage (Table 5a). Nevertheless,
more recently, AnxA5 deficiency caused increased bone overgrowth at the enthesis, and
it was concluded that AnxA5 prevented bone overgrowth triggered by mechanical forces
and modulated expression of mineralization regulators [240].
Likewise, although being the most abundant membrane-associated protein in stere-
ocilia, AnxA5 deficiency was dispensible for hair-bundle development and function [241]
(Table 5a).
6.2. AnxA5 and Anticoagulation
AnxA5 is most abundant in the placenta and associated with thrombophilia-related
complications in pregnancy [242]. Although AnxA5 deficiency was initially not consid-
ered to interfere with embryonal development, in later studies reduced litter size, in-
creased foetal loss and placental thrombosis of maternally homozygous progeny were
reported [243]. Yet, Anxa5−/− mice exhibited regular estrous cycle and ovulation num-
bers [243], although altered pituitary hormone expression patterns were observed [244,245].
Interestingly, administration of heparin to prevent thrombi formation in the placental
circulation reduced pregnancy loss in the AnxA5 KO-mice (Table 5b). Alternatively, admin-
istration of Zinc2+ restored anticoagulation, upregulated AnxA5 levels in the placenta, and
showed a trend to increase litter size in Anxa5−/− mice [246]. Moreover, fusion of AnxA5,
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with strong affinity for outer leaflet PS, with echistatin, which binds to the integrin αIIbβ3
receptor on platelets, showed potential as antithrombotic reagent that specifically targets
platelets in thrombogenesis sites [247]. Based on the property of AnxA5 to recognize PS on
activated platelets, AnxA5-conjugated micelles have been developed to enable targeted
delivery of drugs that promote thrombolysis [248] to alleviate the risk of hemorrhage that
occurs after administration of thrombolytic agents.
In addition, the anticoagulant AnxA5 activity has implications for other diseases, as
administration of wildtype AnxA5, but not an AnxA5 mutant version unable to bind PS,
could overcome dysfunctional coagulation and inhibited thrombin formation in septic
animals [249]. Mechanistically, the ability of AnxA5 to form two-dimensional arrays on
PS-rich membranes in a Ca2+-dependent manner appears critical [242,250]. However, skin
wound inflammation and closure were not altered in Anxa5−/− mice [80]. In fact, increased
levels of AnxA5 in the alveolus may play a detrimental role in alveolar epithelial wound
healing, promoting lung inflammation and fibrosis [251]. Nevertheless, AnxA5-based
approaches could become a suitable tool to overcome poor obstetric outcomes caused by
antiphospholipid syndrome, preeclampsia and SLE in humans [252] (Table 5b,c).
6.3. AnxA5 and Cardiovascular Disease
The ability of AnxA5 to bind cell surface PS on apoptotic cells has proven valu-
able for the diagnosis of atherosclerosis [226] (Table 5d). However, a comparison of
radiolabeled (99mTC) AnxA5 with duramycin in HFD-fed apoE−/− KO-mice identified
99mTC-duramycin to be more suitable for the quantification of vulnerable atherosclerotic
plaque [253]. These technical limitations might have contributed to the inability to detect
any apoptotic changes in the aortic arch of apoE−/− mice treated with low dose radiation,
which is considered to protect against atherosclerosis, when using 99mTC-labeled AnxA5
for autoradiographic analysis [254]. On the other hand, AnxA5-conjugated gold nanopar-
ticles helped to better target localized apoptotic macrophages and diagnose vulnerable
atherosclerotic plaque in the HFD-fed apoE−/− mouse model [255].
The therapeutic potential of recombinant AnxA5 binding to cell surface PS on apoptotic
cells and thereby providing anticoagulant, but also anti-apoptotic and anti-inflammatory
activities was shown in several studies (Table 5d). In apoE−/− mice fed a western style diet,
subsequent AnxA5 administration reduced recruitment and activation of monocytes to the in-
flamed lesion site, thereby reducing plaque inflammation [256]. Moreover, when AnxA5 was
administered simultaneously with the western style diet, reduced apoptotic rates contributed
to the significantly reduced plaque size [257]. Using hypercholesterolemic ApoE*3 Leiden
mice as a model for MI-reperfusion injury, AnxA5 treatment strongly reduced infarct size
and improved cardiac function, most likely via the attenuation of the post-ischaemic inflam-
matory response [258]. Moreover, administration of AnxA5 fused to stromal-derived factor
1, a cytokine that protects the heart from ischaemic injury, accumulated at the myocardium,
probably via binding to PS on apoptotic cells, and provided cardioprotection, as judged by
attenuated apoptosis, enhanced angiogenesis, reduced infarcted size and improved cardiac
function after MI [259]. Finally, AnxA5 administration improved steatosis, inflammation and
fibrosis in nonalcoholic steatohepatitis [260]. Interestingly, the underlying mechanism in the
latter studies might not involve AnxA5 binding to PS, but AnxA5 interacting with pyruvate
kinase 2, leading to metabolic reprogramming from glycolysis to oxidative phosphorylation
in macrophages [260] (Table 5d).
6.4. AnxA5 and Cancer
The ability of AnxA5 to recognize PS exposed by apoptotic cells has been very valuable
in cancer-related studies (Table 5e). It would go beyond the scope of this review to list
all studies that utilized AnxA5 as a read-out to monitor apoptosis, and only research that
specifically examined the contribution of AnxA5 to oncogenesis is summarized here.
In hepatocarcinoma, AnxA5 overexpression promoted in vivo tumour malignancy
and lymphatic metastasis [261], most likely through MAPK and Rac1 signaling path-
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ways [262]. Likewise, AnxA5 upregulation promoted tumourgenicity of glioma cells in
nude mice [263]. On the other hand, AnxA5 knockdown impeded tumourigenesis in subcu-
taneous xenografts from renal cell carcinoma [264], with the latter two studies suggesting
an involvement of PI3K/Akt signaling and implicating AnxA5 as a potential biomarker in
glioma and renal cell carcinoma. In non-small cell lung cancer, drug resistance to first-line
EGFR tyrosine kinase inhibitors is common and AnxA5 depletion restored gefitinib sensi-
tivity by promoting G2/M cell cycle arrest, providing opportunity to overcome this major
clinical challenge [265].
In contradiction to the abovementioned tumour models, AnxA5 high-affinity binding
to PS also inhibited engulfment of apoptotic cells by macrophages, which increased the
immunogenicity of tumour cells undergoing apoptosis. Indeed, treatment of melanoma
xenografts with AnxA5 reduced tumour growth, increased necrosis in tumour tissues
and most strikingly, inhibited angiogenesis by downregulating VEGF production [266].
Hence, targeted delivery of AnxA5 could be utilized to selectively inhibit tumour growth
and progression. Indeed, intra-tumoural release of AnxA5 from intravenously injected
nanoparticles effectively blocked phagocytosis of apoptotic cells, which then triggered a
strong cytotoxic T cell response and immunological memory that led to complete tumour
regression in 50% of mice with orthotopic breast tumours [267]. Likewise, AnxA5 admin-
istration lessened the immunosuppressive properties of the tumour microenvironment
generated by cisplatin treatment and enhanced the immunogenicity and anti-tumour effi-
cacy in a preclinical tumour model with a defined tumour-specific antigen (TC-1 tumour
model) [268,269]. Along these lines, fusion of AnxA5 with the peptide-major histocompati-
bility complex strongly augmented lymphocyte response, which could serve to improve
immune modulation for cancer therapy [270]. In a mouse model for ovarian cancer, the de-
livery of AnxA5 fused to an enzyme that converts selenomethionine to toxic methylselenol,
in combination with anti-CD73 and anti-Ox40 as immunostimulants, strongly decreased
tumour burden in mice with orthotopic metastatic ovarian cancers [271] (Table 5f).
6.5. AnxA5 and Imaging
As molecular imaging techniques using radiolabeled AnxA5 provided opportunity
to more rapidly assess apoptosis in disease or upon therapy, efforts over the last few
years improved the imaging methodology based on AnxA5-derived tools to monitor
apoptosis in vivo (Table 5d–f). As mentioned above, 99mTC radiolabeled AnxA5 and
AnxA5-conjugated gold nanoparticles were valuable diagnostic imaging tools in mouse
models for atherosclerosis [253–255] (Table 5d). AnxA5 dual-labeled with 99mTC and
Alexa Fluor 568 allowed detection of ethanol-induced cell death in the femur muscle but
failed to visualize cell death in a murine model for stroke [272]. Imaging of apoptosis
using 111In- and DOTA-peptide -labeled AnxA5 monitored efficacy of suicide gene therapy
after treatment with ganciclovir in NG4TL4 sarcoma expressing herpes simplex virus
thymidine kinase [273]. Drug-induced apoptosis in tumour-bearing mice was also de-
tectable using AnxA5-conjugated ultrasmall superparamagnetic iron oxide [274]. A novel
AnxA5-conjugated nano-sized ultrasound contrast agent was able to detect apoptotic cells
inside tumours after chemotherapy [275] (Table 5e). Magnetic beads coated with AnxA5
were recently used to isolate tumour-derived extracellular vesicles from mouse models
xenografted with human cancer cells, an approach with diagnostic and therapeutic po-
tential [276]. Another alternative to 99mTc-AnxA5, which has limitations for non-invasive
molecular imaging in the clinic [277], is 68Ga-labeled AnxA5, which efficiently visualized
hepatic apoptosis in an anti-Fas antibody mouse model and efficacy of established chemo-
and radiotherapies in animals with Burkitt’s lymphoma [278]. Alternatively, fusion of
AnxA5 with a mutant of Renilla luciferase created a new and sensitive biosensor that
effectively detected vascular apoptosis in ethanol-induced corneal apoptosis in mice [279].
Interestingly, labeling of AnxA5 with a pH-sensitive probe that emits fluorescence upon
pH decrease provided opportunity to monitor efferocytosis, the clearing of apoptotic cells
by phagocytosis [280] (Table 5f).
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6.6. Other PS-Related Aspects of AnxA5 Biology
Other AnxA5-related biological activities reviewed in more detail elsewhere include
viral infection, membrane invagination and membrane repair [11,226,281–283]. In addition,
AnxA5-KO mice showed a strongly reduced allogeneic reaction against primary and
secondary necrotic cells as well as carcinoma cells [284,285]. This could also be relevant for
preventing viral infections, including human immunodeficiency virus, which together with
infected monocytes/macrophages, exposes increased amounts of PS on the surface [284]
(Table 5f). Possibly relevant in this context is the ability of the core domain of AnxA5 and
several other annexins to interact with Dectin-1, which facilitates uptake of apoptotic cells
by dendritic cells and is an important mechanism for establishing peripheral tolerance to
self-antigens [286].
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Table 5. Phenotypes observed in AnxA5 in vivo models.
(a) AnxA5 and Development
Tissue/Disease Model Phenotype Mechanism Ref
Embryonal development Targeted AnxA5-lacZ expression Expression in perivascular cells ofnon-skeletal tissues
Angiogenesis differentiation?
Endothelial cell maturation? [234,235]
Bone and cartilage development AnxA5 KO-mice; AnxA5/A6Double-KO mice
Normal calcification during skeletal
development [236,238,239]
Bone cartilage development AnxA5 KO-mice Bone overgrowth at enthesis AnxA5 prevents bone overgrowthtriggered by mechanical forces [240]
Hair bundle development AnxA5 KO-mice Normal stereocilia [241]
(b) Anxa5 and Anticoagulation
Tissue/Disease Model Phenotype Mechanism Ref
Placenta Maternal AnxA5 KO-mice Reduced litter size; Increased risk offoetal loss; Placental thrombosis
AnxA5-mediated anticoagulation
via Ca2+-dependent binding and




Zn2+ rescued anticoagulation and




AnxA5 levels in WT mice
[246]
Thrombosis Administration of echistatin-AnxA5fusion protein to WT mice
Improved clotting and reduced
wound healing time
Echistatin-annexin V fusion protein
targets integrin αIIbβ3 receptor and
PS on platelets in thrombogenesis
sites
[247]
Carotoid thrombosis FeCl3-induced carotid thrombosis inWT mice
AnxA5-conjugated micelles for
delivery of thrombolytic enzymes
AnxA5 binding to PS provides drug
delivery for targeted thrombolysis [248]
Thrombosis in abdominal sepsis Administration of WT and mutantAnxA5 in septic animals AnxA5 inhibits thrombin formation
Ca2+-dependent binding of WT, but
not mutant AnxA5, to PS
[249]
Thrombus formation after blood
vessel injury
Administration of AnxA5 dimer in
laser-induced injury and tail tip
bleeding model
AnxA5 inhibits thrombin formation
and clot formation
Ca2+-dependent binding of AnxA5
dimer to PS-exposing platelets
[252]
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Table 5. Cont.
(c) AnxA5 and Wound Repair, Inflammation
Disease Model Phenotype Mechanism Ref
Skin wound repair AnxA5 KO-mice; Exogenous AnxA5administration Skin wound repair unaltered
AnxA5 binding to PS? Membrane
repair? [80]
Lung fibrosis and inflammation Aerosol delivery of AnxA5 Alveolar AnxA5 promotes lunginflammation and fibrosis AnxA5 binding to PS and signaling? [251]
Muscle dystrophy Myofibers from ANO5 KO-mice Loss of Anx-dependent capformation at injury site Diminished AnxA5 at injury site [287]
(d) AnxA5 and Cardiovascular Disease
Disease Model Phenotype Mechanism Ref
Diagnosis/detection of
atherosclerotique plaque
HFD-fed ApoE KO-mice; Other
CVD models
Radio-, fluorescently labeled AnxA5
or AnxA5-conjugated gold particles
to detect plaque
AnxA5 binding to PS on apoptotic
cells [226,253–256]
Detection of cell death in stroke Ethanol-induced cell death in femurmuscle vs. stroke in mice
Dual-labeled AnxA5 (99mTC, Alexa)
to detect apoptosis
Dual-labeled AnxA5 failed to
recognize cell death in stroke [272]
CVD treatment AnxA5 administration in HFD-fedApoE KO- mice
Reduced plaque inflammation and
plaque size
AnxA5 binding to PS on apoptotic





Reduced plaque inflammation and
plaque size
AnxA5 binding to PS on apoptotic
cells [258]
MI SDF-1-AnxA5 fusion proteintreatment in MI mouse model Cardioprotection





HFD-induced NASH mouse model
AnxA5 improves steatosis,
inflammation and fibrosis
AnxA5 binding to PKM2 in




(e) AnxA5 and Cancer
Disease Model Phenotype Mechanism Ref
Hepatocellular carcinoma AnxA5 overexpression in Hca-Pxenografts Increased growth and metastasis MAPK and Rac1 signaling [261,262]
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Table 5. Cont.
Glioblastoma
Intracranial glioma mouse model:
implanted U97 cells ± AnxA5
depletion/overexpression
AnxA5 promotes glioma
tumourgenicity PI3K/Akt/NFκB signaling? [263]
Renal cell carcinoma AnxA5 depleted Caki-1 xenografts Reduced tumourgenicity Reduced PI3K/Akt/mTORC1activity and MMP expression [264]
Gefitinib resistance in non-small cell
lung cancer
AnxA5 knockdown in
gefitinib-resistant PC9 xenografts Restoration of gefitinib sensitivity
G2/M cell cycle arrest, inhibition of
apoptosis [265]
Melanoma AnxA5 administration in B16F10xenografts
Reduced tumour size; Increased
tumour necrosis
Reduced VEGF expression and
angiogenesis [266]
Breast cancer immunotherapy Intra-tumoural AnxA5 release in4T1 breast tumours
AnxA5 triggers anti-tumour
immune response that leads to
tumour regression
AnxA5 binds PS on apoptotic cells
to block phagocytic clearance,





cisplatin treatment in TC-1 tumour
model
AnxA5 increases immune response
and alleviates cisplatin-mediated
immunosuppression
AnxA5 can deliver antigenic
peptides to the tumour environment [268–270]
Ovarian cancer prodrug and
imunotherapy
Targeted delivery of mCTH-AnxA5
fusion protein together with
immunostimulants to ID8 tumours
AnxA5 targets mCTH to tumour to
convert nontoxic to toxic drug,
increased cell death improves
immune-directed tumour
destruction
AnxA5 binding to PS on tumour
and tumour vasculature as vehicle
to enable enzyme-prodrug approach
[271]






AnxA5 monitors drug efficacy
AnxA5 binding to PS on apoptotic
tumour cells [273]







detects cancer cell apoptosis
AnxA5 binding to PS on apoptotic
tumour cells [274]
Detection of cancer cell death after
chemotherapy
Cisplatin-treated MDA-MB-231
xenografts AnxA5-conjugated magnetic beads
AnxA5 binding to PS on apoptotic
tumour cells assessed by ultrasound [275]
(f) AnxA5 and Detection of EVs and Apoptosis
Tissue/Disease Model Phenotype Mechanism Ref
Detection of extracellular vesicles
(EVs) Human HCC827 xenografts AnxA5-conjugated magnetic beads
AnxA5 binding to PS enables EV
isolation [276]
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Table 5. Cont.
Detection of liver apoptosis and
cancer





AnxA5 binding to PS on apoptotic
cells [277,278]
Vascular apoptosis Ethanol-induced corneal apoptosisin mice
AnxA5 fused to Renilla luciferase
mutant as biosensor
AnxA5 binding to PS on apoptotic
cells [279]
Efferocytosis
Injection of Jurkat cells labeled with
pH-sensitive AnxA5 probe into
peritoneal cavity of mice
Ex vivo measurement of
phagocytosis of apoptotic cells by
peritoneal macrophages
AnxA5 binding to PS and exposure
to different pH environments [280]
Immunogenicity of apoptotic cells Induction of necrosis by mechanicalstress in AnxA5-KO mice
AnxA5 is required for immune
response against dead cells
AnxA5 binding to PS on apoptotic
cells [284,285]




Dectin-1 on dendritic cells binds to
core domain of annexins (incl.
AnxA5) for uptake of apoptotic cells
to establish tolerance for
self-antigens
[286]
Abbreviations: Akt, protein kinase B; ANO5, anoctamin-5; Anx, annexin; apoE, apolipoprotein E; Ca2+, calcium; CVD, cardiovascular disease; EVs, extracellular vesicles; HFD, high-fat diet; KO, knockout; mCTH,
mutated cystathionine gamma-lyase; MI, myocardial infarction; MMP, matrix metalloproteases; mTORC1, mammalian target of rapamycin complex 1; NASH, nonalcoholic steatohepatitis; PKM2, pyruvate kinase
2; PS, phosphatidylserine; SDF-1, stromal cell-derived factor 1; STAT3, signal transducer and activator of transcription 3; TK, thymidine kinase; VEGF, vascular endothelial growth factor; WT, wildtype.
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7. AnxA6
AnxA6 is highly and ubiquitously expressed, except in epithelial cells of the small intestine,
colon and parathyroid gland [1–3,10,288]. AnxA6 is mainly found at the plasma membrane, endo-
and exocytic vesicles, but also in mitochondria and lipid droplets [1–4,9,288–290]. AnxA6 consists of
eight rather than four annexin repeats and interacts with a variety of proteins and lipids to regulate
microdomain organization, endo- and exocytosis, cholesterol transport, signal complex (dis-)
assembly, cytoskeleton rearrangements, and stress response. Hence, AnxA6 has been associated
with cell growth and motility, differentiation, lipid and glucose homeostasis [1–4,9,10,288,291,292],
as well as membrane repair [293–295] and viral infection [296–298].
Alternative splicing generates two isoforms, AnxA6-1 and AnxA6-2, the latter lacking
six amino acids at the C-terminus (pos. 524–529) [288,299]. The AnxA6-1 isoform is
abundant in most cells and tissues, while AnxA6-2 is upregulated in some transformed cell
lines [288,300,301] and isoform-specific functions related to Ca2+ homeostasis and endo-
/exocytosis may exist [288,302–304], but in vivo evidence supporting these observations is
still lacking. Interestingly, computational models suggested limited overlap, but rather a
diversity of functions associated with the two AnxA6 isoforms [305].
7.1. AnxA6 and Cardiac Function
Initial studies with mice overexpressing AnxA6 in the heart led to enlarged dilated
hearts, acute diffuse myocarditis, lymphocyte infiltration and fibrosis throughout the heart
and pulmonary veins, ultimately causing heart failure [306] (Table 6a). Furthermore, car-
diomyocytes from Anxa6−/− mice showed higher contractility and accelerated removal of
diastolic Ca2+ from the cytoplasm [307]. Hence, AnxA6 scaffold and membrane organizer
functions probably regulate Ca2+-dependent ion pumps and/or exchangers. In addition,
Ca2+ signaling and stimulus–response coupling in the heart were altered in mice over-
expressing a dominant-negative N-terminal AnxA6 mutant [308]. As other N-terminal
AnxA6 deletion mutants compromised endocytosis and signaling [309–313], these mu-
tants probably lack Ca2+-dependent membrane-binding properties and remain cytosolic,
trapping their interaction partners in the cytosol (Table 6a).
Nevertheless, AnxA6 deficiency in mice was not associated with alterations in the
heart rate, blood pressure, cardiovascular response to septic shock or changes in B or T cell
development [314] (Table 6a), challenging proposed AnxA6 functions in the heart and in
lymphocyte differentiation [306–308,315].
7.2. AnxA6 and Skeletal Development
AnxA6 is highly expressed in bone and skeletal muscle, yet Anxa6−/− animals and
even double KO-mice lacking AnxA6 and AnxA5 did not reveal defects in skeletal devel-
opment [238,239] (see also Section 6.1). However, in later studies, a reduction in the growth
plate length and number of chondrocytes in newborn AnxA6 KO-mice was observed,
which correlated with reduced mineralization of growth plate cartilage [316]. In addition,
Anxa6−/− chondrocytes exhibited delayed terminal differentiation, markedly decreased
intracellular Ca2+ levels upon ascorbic acid stimulation and reduced PKCα membrane
translocation and activity, the latter possibly decreasing MAPK signaling required for
chondrocyte differentiation [316] (Table 6b).
In studies mimicking osteoarthritis, knee cartilage destruction after IL-1β injection
or partial meniscectomy was strongly reduced in AnxA6 KO-mice [317]. Mechanisti-
cally, the loss of AnxA6 interacting and promoting nuclear translocation of NFκB, a major
driver in the pathogenesis of osteoarthritis, could be responsible for this phenotype. Fur-
thermore, in articular chondrocytes from control animals, AnxA6 associates with the
plasma membrane to interfere with Wnt/b-catenin signaling, affecting crosstalk with
NFκB signaling, catabolic and inflammatory events, all of which contributing to cartilage
degradation in osteoarthritis [318].
The ability of AnxA6 to influence the organization of cholesterol-rich plasma mem-
brane microdomains [1–4,288,319] on neuronal cells also appears relevant in osteoarthritis.
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AnxA6 KO-mice displayed increased sensitivity to mechanical stimuli due to elevated
activity of the cation channel Piezo2 in sensory neurons, which mediates mechano-gated
current linked to body awareness and touch [320]. Moreover, AnxA6 overexpression atten-
uated mechanical pain, indicating therapeutic potential to inhibit chronic mechanical pain
commonly associated with osteoarthritis (Table 6b).
7.3. AnxA6 and Immune Response
Although AnxA6 is upregulated during B and T lymphocyte differentiation [315],
unchallenged Anxa6−/− mice exhibited a normal B and T cell development [314], including
a normal repertoire of CD3+, CD4+, CD8+, naïve (CD62L+CD44−), effector (CD62L−CD44+)
and memory (CD62L+CD44+) T lymphocytes [321]. However, after triggering a delayed-
type contact hypersensitivity reaction upon dermal exposure to an irritant, the local tis-
sue swelling and clonal expansion of T cells in the lymph nodes from AnxA6 KO-mice
contained significantly less proliferating CD4+ T lymphocytes [321] (Table 6c). Further-
more, IL-2 signaling, critical to elicit T cell proliferation, was impaired in AnxA6-deficient
T cells [321]. This correlated with reduced plasma membrane order of AnxA6−/− T
cells, suggesting an improper formation of specialized (cholesterol-rich) membrane mi-
crodomains (lipid rafts), interfering with appropriate IL-2 receptor signaling during im-
mune response [288,321,322].
Along these lines, membrane order and protein distribution in rafts and non-rafts
was also altered in mesenchymal mouse embryo Anxa6−/− fibroblasts [319] (Table 6d).
These membrane-organizing functions of AnxA6 might also affect other immune responses,
as AnxA6-deficient mice showed reduced bacterial clearance after oral challenge with
Citrobacter rodentium, indicating a higher susceptibility to infection (The Wellcome Trust
Sanger Institute Mouse Genetics Project, Database Release 2011; http://www.informatics.
jax.org/reference/J:175295; accessed 12 March 2021).
7.4. AnxA6 and Lipid and Glucose Homeostasis
AnxA6 has been linked to lipoprotein and cholesterol uptake and transport, cytokine
secretion as well as signaling events related to lipid and glucose homeostasis [4,9,288,292],
which appear relevant in liver and adipose physiology (Table 6e).
AnxA6 was found associated with lipid droplets in adipocytes [323,324] and AnxA6
upregulation in 3T3 adipocytes lowered triglyceride storage and secretion of adiponectin,
which exerts beneficial effects on glucose and lipid homeostasis [323,324]. Vice versa, serum
adiponectin levels were increased in AnxA6-deficient mice. As AnxA6 levels increased in WAT
of obese mice, this may contribute to impaired lipid storage and adiponectin release associated
with obesity [324]. AnxA6 is also associated with hepatic lipid droplets [290,325], with primary
Anxa6−/− hepatocytes and liver sections of AnxA6 KO-mice showing reduced triglyceride
accumulation and lipid droplet numbers [325]. As AnxA6 up- and downregulation occurs in
hepatic lipid disorders, this may implicate a novel role for AnxA6 in fatty acid and triglyceride
metabolism in the liver [325].
During the course of HFD-feeding, AnxA6 KO-mice gained less weight, in particular
in WAT, compared to controls [326]. HFD-feeding caused elevated total plasma triglyc-
erides and cholesterol levels, yet an overall lipoprotein profile commonly associated with
increased insulin sensitivity was observed [326–328]. Indeed, AnxA6 deficiency resulted
in increased hepatic insulin signaling and improved glucose clearance [326]. However,
HFD-fed AnxA6 KO-mice failed to properly downregulate hepatic gluconeogenesis and
revealed increased glycogen storage in the liver, implicating AnxA6 in the fine-tuning of
hepatic glucose metabolism and systemic control of glucose [326] (Table 6e).
Strikingly, when the ability to regenerate the liver was challenged after partial hep-
atectomy (PHx), AnxA6-deficient mice exhibited a significantly lower survival rate after
PHx [329]. This striking phenotype was not due to defects in hepatocyte cell cycle progres-
sion, or the delayed onset of steatosis in these animals, but a prolonged hypoglycaemia,
which could not accommodate the heavy energy requirements in AnxA6−/− animals after
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PHx. Mechanistically, shuttling of the Na+-coupled neutral amino acid transporter SNAT4
to the hepatocyte plasma membrane, which provides alanine as fuel to drive gluconeoge-
nesis and fatty acid synthesis during liver regeneration, was compromised in Anxa6−/−
mice [329]. Such a decisive role in the post-hepatectomy phase has yet been documented
only for a rare number of genes [330–332].
The liver is central for cholesterol homeostasis and contains abundant amounts of
AnxA6 [333], with potential roles in the uptake and internalization of LDL-derived choles-
terol [309,310,334,335]. Moreover, AnxA6 overexpression induced cholesterol accumulation
in late endosomes, a phenotype reminiscent of the Niemann-Pick type C1 (NPC1) muta-
tion [336]. Outstandingly, AnxA6 depletion in NPC1 mutant cells alleviated cholesterol
accummulation by restoring cholesterol export to the endoplasmic reticulum via Rab7 and
StAR-related lipid transfer domain-3 (StARD3)-dependent formation of membrane contact
sites [337]. In line with these findings, Rab7-GTP levels were elevated in mouse embryo
fibroblasts from Anxa6−/− mice [337], indicating that the gatekeeper function of AnxA6
to control cholesterol transport from late endosomes could be relevant in vivo and the
progression of NPC disease [338] (Table 6e).
In NPC disease, late endosomal cholesterol accumulation due to the loss of NPC1
primarily affects the brain, causing neuronal damage and affecting motor coordination.
In addition, considerable liver malfunction is also common. Strikingly, lack of AnxA6
in NPC1-deficient animals (Npc1−/−/Anxa6−/−) did not prevent cerebellar degenera-
tion [339]. Furthermore, livers of the AnxA6-deficient NPC1 KO-animals contained a
significantly elevated number of foam cells congesting the sinusoidal space, which is
commonly associated with inflammation, further deteriorating their compromised hepatic
functions and reduced lifespan [339].
Lipid droplet numbers, cholesteryl esters and glycogen granules were strongly decreased
in livers from Npc1−/−/Anxa6−/− mice, indicating a much higher turnover of cholesteryl esters,
other neutral lipids and glycogen compared to NPC1 KO-animals [339]. In addition, and reflect-
ing observations in liver, retina and primary fibroblasts from Anxa6−/− mice [289], morpholog-
ically altered mitochondria in Anxa6−/− hepatocytes were apparent [339]. In agreement with
AnxA6 depletion rescuing the NPC1 mutant phenotype [337,338], AnxA6 deficiency slightly
improved compromised mitochondrial morphology [340,341] and possibly inter-organelle
communication in Npc1−/− animals [339] (Table 6e).
7.5. AnxA6 and Cancer
Numerous studies identified AnxA6 to exhibit tumour suppressing as well as tumour
promoting activities, depending on the cancer cell type and degree of malignancy [311,342,343].
These opposing activities probably relate to the multiple and diverse AnxA6 scaffolding
functions, which are likely to differ in the various cancer cells due to the different repertoire
and availability of interaction partners. Besides data from cell culture models or expression
analysis of patient cohorts, several studies in recent years examined roles for AnxA6 in tumour
growth and progression in vivo (Table 6f).
In EGFR overexpressing A431 epithelial carcinoma lacking endogenous AnxA6 [311,312],
restoration of AnxA6 expression promoted PKCα-mediated threonine 654-EGFR phospho-
rylation, which inhibited EGFR tyrosine kinase activity, cell growth, migration and inva-
sion [313,344]. AnxA6 overexpression in these A431 cells also reduced growth and EGFR
activity in A431 xenografts in a PKCα-dependent manner [345,346]. Moreover, AnxA6 up-
or downregulation impacted on the efficacy of tyrosine kinase inhibitors to inhibit growth,
migration and invasion of EGFR-related cancer cells [346].
In a TNBC model using BT-549 xenografts, AnxA6 depletion was associated with early
onset and rapid growth of tumours, which correlated with poor overall survival of basal-
like TNBC patients [347]. These studies identified RasGRF2, a Ras protein specific guanine
nucleotide exchange factor (RasGEF), as an additional effector besides PKCa and p120
GTPase activating protein [3,8,311,312], to confer AnxA6-dependent roles in cell growth
and motility [347]. In fact, the inverse relationship of AnxA6 and RasGRF2 expression levels
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discriminated rapidly growing from invasive TNBC subsets [348]. This could be relevant for
subset-specific therapeutic interventions, as AnxA6 upregulation was associated with the
response of TNBC cells to cytotoxic and/or EGFR-targeted therapies and the development
of drug resistance [343,349] (Table 6f).
Significant amounts of AnxA6 are found in late endosomes/(pre-) lysosomes [9,288,292,335–337].
Inner membranes from this compartment can fuse with the plasma membrane to be released as extracel-
lular vesicles (EVs) [4,292,350]. These EVs, including exosomes, are highly enriched in annexins, including
AnxA6 (ExoCarta exosome database: www.exocarta.org; accessed 12 March 2021) and are believed to
facilitate cell–cell communications and influence recipient cell behaviour.
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Table 6. Phenotypes observed in AnxA6 in vivo models.
(a) AnxA6 and Cardiac Function
Tissue/Disease Model Phenotype Mechanism Ref
Cardiomyopathy Heart failure Heart-specific AnxA6 WT/mutantoverexpression
Amplitude Ca2+ transients; Ca2+




Cardiac function AnxA6-KO cardiomyocytes Ca





Cardiac function AnxA6 KO-mice Normal cardiac function Redundancy? [312]
(b) AnxA6 and Skeletal Development
Tissue/Disease Model Phenotype Mechanism Ref
Bone and cartilage development AnxA6 KO-mice;AnxA5/A6 Double-KO mice Normal skeletal development Redundancy? [238,239]
Bone and cartilage development AnxA6 KO-mice, Newborns
Reduced mineralization of growth
plate cartilage;
Delayed chondrocyte differentiation
Loss of AnxA6-dependent PKCα
translocation and signaling [316]
Osteoarthritis AnxA6 KO-mice Reduced knee cartilage destruction Loss of AnxA6/p65 (NFκB)interaction [317,318]
Pain in osteoarthritis AnxA6 KO-mice Increased sensitivity tomechanical/chronic pain stimuli
Increased cation channel Piezo2
activity in sensory neurons [320]
(c) AnxA6 and Immune Response
Tissue/Disease Model Phenotype Mechanism Ref
Immune system AnxA6 KO-mice Normal B and T cell development Redundancy? [314]





(d) AnxA6 and Homeostasis
Tissue/Disease Model Phenotype Mechanism Ref
Membrane order AnxA6-KO MEFs Microdomain organisation Membrane domain/lipiddistribution [319]
Ca2+ homeostasis
AnxA6-KO (liver, retina) AnxA6-KO
MEFs Dysfunctional mitochondria Loss of AnxA6/Drp1 interaction [289]
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Table 6. Cont.
(e) AnxA6 and Lipid/Glucose Homeostasis
Tissue/Disease Model Phenotype Mechanism Ref
Adipose tissue AnxA6 KO-mice







Liver regeneration AnxA6 KO-mice Hypoglycemia; De-regulatedhepatic gluconeogenesis
Loss of alanine uptake and SNAT4
transporter cell surface localization [329]
HFD-induced fatty liver and insulin
resistance AnxA6 KO-mice
Altered insulin signaling; Increased
glycogen storage; Failure to
downregulate hepatic
gluconeogenesis
Loss of AnxA6 scaffold and
membrane transport functions [326]
Neuronal damage, motor
coordination
AnxA6 KO-mice; NPC1 KO-mice;
AnxA6/NPC1 Double-KO mice
Normal in AnxA6-KO; Cerebellar








compared to NPC1-KO: Increased
liver inflammation; Altered
mitochondrial morphology; Higher
turnover of neutral lipids and
glycogen; Reduced lifespan





(f) AnxA6 and Cancer
Disease Model Phenotype Mechanism Ref
EGFR-related cancer AnxA6 overexpression in A431xenografts
Reduced tumour growth; Impact on
EGFR-targeted drug efficacy
AnxA6-mediated and PKCα- and





AnxA6 depletion in BT-549
xenografts
Early onset and rapid tumour
growth; Impact on EGFR-targeted
drug efficacy
AnxA6- and RASGRF2- dependent
EGFR/Ras/MAPK signaling [347–349]
Drug resistance in breast cancer MMTV-PyMT and 4T1 breast cancermodels
Chemotherapy-elicited secretion of
AnxA6-containing EVs from






Int. J. Mol. Sci. 2021, 22, 3439 39 of 67
Table 6. Cont.
Pancreatic ductal adenocarcinoma
(PDAC) PDAC mouse model
ANXA6-depleted EVs from CAFs
impaired PDAC and metastasis
CAF-cancer cell communication via
ANXA6/LRP1/TSP1 [352]
Gastric cancer NUGC3 xenografts AnxA6-containing EVs from CAFscontribute to drug resistance
AnxA6-mediated activation of
integrin β1, FAK and YAP1 [353]
(g) AnxA6 and Membrane Repair
Disease Model Phenotype Mechanism Ref
Muscle dystrophy AnxA6-KO in zebrafish Impaired membrane repair Cooperation with dysferlin [293]
Muscle dystrophy Mouse models with Dysferlinmutations
Impaired AnxA6 recruitment for
membrane repair
Cooperation with dysferlin and
other annexins to seal injured
membrane
[354–356]
Muscle dystrophy Mouse models for musculardystrophy
AnxA6 is a modifier gene required
for membrane repair after muscle
injury
AnxA6 mutants contribute to
defects in sarcolemma resealing [295]
Muscle dystrophy Mouse models for musculardystrophy
Delivery of AnxA6 promotes





Muscle dystrophy Myofibers from ANO5 KO-mice Loss of Anx-dependent capformation at injury site
Lack of AnxA6 accumulation at
injury site [287]
Abbreviations: ANO5, anoctamin-5; Anx, annexin; Ca2+, calcium; CAFs, cancer associated fibroblasts; Drp1, dynamin-related protein 1; EGFR, epidermal growth factor receptor; EVs, extracellular vesicles; FAK,
focal adhesion kinase; HFD, high-fat diet; IL, interleukin; KO, knockout; LRP1, low density lipoprotein receptor related protein 1; MAPK, mitogen-activated protein kinase; MMTV-PyMT, mouse mammary
tumor virus-polyoma middle tumor-antigen; NFκB, nuclear factor kappa B; p120GAP, p120 GTPase activating protein; PDAC, pancreatic ductal adenocarcinoma; PKCα, protein kinase Cα; RASGRF2, Ras
protein specific guanine nucleotide exchange factor; SNAT4, sodium-coupled neutral amino acid transporter 4; TNBC, triple negative breast cancer; TSP1, thrombospondin 1; WAT, white adipose tissue. YAP1,
yes-associated protein 1.
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In two mouse models of breast cancer (MMTV-PyMT, 4T1), taxane and anthracycline
therapy induced secretion of EVs from tumours with enhanced metastatic capacity. These
chemotherapy-elicited EVs were enriched with AnxA6 and promoted NFκB-dependent
endothelial activation, cytokine secretion and monocyte subtype expansion in the pul-
monary pre-metastatic niche to establish lung metastasis [351]. Hence, AnxA6 enrichment
on EVs might be useful to develop a biomarker to predict the risk for metastasis in patients
with poor response to chemotherapy. Similarly, AnxA6-positive EVs from CAFs sup-
ported PDAC aggressiveness, and was restricted to PDAC patients, making it a potential
biomarker for PDAC grade [352]. Along these lines, AnxA6-containing EVs from CAFs also
contributed to drug resistance in a peritoneal metastasis mouse model for gastric cancer,
possibly via activation of integrin β1, focal adhesion kinase (FAK) and yes-associated
protein 1 (YAP) signaling [353]. The identification of a monoclonal AnxA6 antibody with
anti-invasive properties on aggressive pancreatic, lung squamous and breast cancer cells
further supports pro-metastatic activity of extracellular AnxA6 [113] (Table 6f).
7.6. AnxA6 and Membrane Repair
Studies in human and rodent cell-based models implicated several annexins, includ-
ing AnxA6, in membrane repair [11,287,294]. Likewise, in zebrafish, AnxA6 was rapidly
recruited to damaged sarcolemma and cooperated with dysferlin to repair membrane
lesions [293] (Table 6g). In this transparent and powerful model organism for the study of
vertebrate biology, AnxA6 and other annexins accumulated at the site of muscle damage,
with AnxA6 deficiency leading to myopathy [293]. Loss of dysferlin was also accom-
panied by impaired AnxA6 translocation and resealing after sarcolemmal disruption in
mouse models [354]. Strikingly, in a mouse model of muscular dystrophy, a naturally
occurring AnxA6 splice variant created a truncated AnxA6 protein lacking four of the
eight annexin repeats. This mutant acted in a dominant-negative manner and interfered
with membrane recruitment of full-length AnxA6 to substantially decrease efficiency of
membrane repair [295]. Other genetic modifiers of muscular dystrophy also interfered
with AnxA6 recruitment for sarcolemma resealing [355]. High resolution microscopy of
muscle after laser injury revealed rapid recruitment of AnxA6 and other annexins (AnxA1,
A2, A5) to damaged sarcolemma, contributing to the formation of a tight cap in a Ca2+- and
actin-dependent manner over a vesicle-rich repair zone [11,287,295,356]. Interestingly, in-
termittent glucocorticoid treatment enhanced muscle repair, through increased expression
of AnxA6 and AnxA1, without eliciting the well-known effect of steroids to trigger muscle
atrophy [357]. Alternatively, administration of recombinant AnxA6 may protect against
acute muscle injury, as it was capable to reseal injured membrane in mouse models [358]
(Table 6g).
8. AnxA7
In contrast to all other annexins, AnxA7 contains a long (100 aa) hydrophobic N-
terminus (Figure 1), with alternative splicing generating a 47 kD isoform found in all
tissues except skeletal muscle, and a 51 kD isoform expressed in the heart, brain and
myotubes [359]. AnxA7 is predominantly associated with secretory vesicles, the plasma
membrane and the nuclear envelope in a Ca2+-dependent manner [360]. Many reports sup-
port AnxA7 to have GTPase activity and contribute to the regulation of Ca2+ homeostasis,
exocytic pathways, and prostaglandin production, with consequences for pancreatic and
cardiac functioning and inflammatory myopathies [361–367], but also cell survival and
tumour growth [368,369].
8.1. AnxA7 and Pancreatic β-Cell Function
The first study examining the targeted disruption of the AnxA7 gene reported an
embryonic lethality due to cerebral haemorrhage in homozygous AnxA7−/− mice [361].
Yet, heterozygous Anxa7+/− mice of this strain were viable and the pancreas of these
animals exhibited islet hyperplasia, β-cell hypertrophy, aberrant metabolic gene expression
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patterns and reduced inositol 1,4,5-trisphosphate receptor levels. The latter was considered
responsible for defects in the Ca2+ release from intracellular stores, compromising Ca2+-
dependent insulin secretion. In follow-up studies, altered ryanodine receptor (RyR) -
mediated Ca2+ release was also related to abnormal insulin secretion from β-cells of these
Anxa7+/− mice [370]. In contrast, an independently generated second AnxA7 KO-strain was
viable and lacked any defect in Ca2+-induced and cAMP-mediated insulin secretion [371].
The different genetic background, design and integration sites of the targeting construct,
orientation of the inserted neo gene and possible consequences for neighbouring genes
could possibly explain the strikingly different phenotypes of the two Anxa7−/− strains [371]
(Table 7a).
8.2. AnxA7 and Cardiac Function
AnxA7 is highly expressed in the heart and based on its possible role in Ca2+ home-
ostasis, adult cardiomyocytes from the viable AnxA7 KO-strain were analyzed [371].
These studies identified the misfunctioning of the apparatus responsible for cardiac muscle
contraction, most likely due to defects in Ca2+ homeostasis [371]. In fact, AnxA7 interacts
with Sorcin and RyR, which both couple Ca2+ channels to the contractile machinery in
cardiac muscle [372], indicating that the loss of these interactions might contribute to the
cardiac phenotype in Anxa7−/− animals [371,373].
In addition, the viable Anxa7−/− strain showed increased susceptibility to atrial fib-
rillation and ventricular tachycardia, both electrophysiological properties linked to the
development of heart arrhythmia [374]. Furthermore, in atrial and ventral tissues of the
Anxa7−/− mice, impaired integrity of the basement membrane of cardiomyocytes and
lack of collagen fibers in intracellular spaces was observed, possibly contributing to the
de-regulated conductive properties of these animals [374]. Moreover, when examining
the consequences of increased resistance to blood flow out of the heart upon transverse
aortic constriction, a well-established surgical procedure to induce cardiac hypertrophy,
the increase in the ratio of heart to body weight was more pronounced in AnxA7 KO-mice.
AnxA7-dependent cardiac activity of the transcription factor NFAT (nuclear factor of acti-
vated T cells), regulating genes involved in the hypertrophic response following cardiac
stress conditions, could contribute to the observed phenotype [367] (Table 7a).
8.3. AnxA7 and Eryptosis
Besides cardiac complications, red blood cells from Anxa7−/− mice were characterized
by an altered cell shape and increased resistance to osmotic shock [375]. Inspection of
eryptosis, the suicidal death of erythrocytes, uncovered hyperosmotic shock, Cl- removal or
energy depletion to trigger enhanced COX-mediated prostaglandin E2 (PGE2) production
in Anxa7−/− erythrocytes [376]. This elicited cytosolic Ca2+ elevation, subsequent PS
exposure at the cell surface, and ultimately, apoptotic death. Eryptosis was also accelerated
in Plasmodium-infected Anxa7−/− erythrocytes, indicating that AnxA7 downregulation may
partially protect against malaria in vivo [377]. Although several annexins have previously
been proposed to inhibit PLA2 [1,2,10], which acts immediately upstream of COX in the
prostaglandin synthesis pathway, only pharmacological inhibition of COX, but not PLA2,
abolished the differences in parasitemia and erythrocyte survival between Anxa7−/− and
wildtype animals [377] (Table 7a).
Further supporting an inhibitory role for AnxA7 in PGE2 production, glucocorticoid-
induced gastric acid secretion, which requires simultaneous downregulation of COX-
mediated PGE2 production, was compromised in Anxa7−/− mice [378].
Additionally, plasma prostaglandin levels and hepatic COX activity were significantly
elevated in AnxA7 KO-mice [366]. As PGE2 upregulation can induce insulin resistance in
hepatocytes, this might contribute to the decreased glucose tolerance observed in these
animals. Pharmacological COX inhibition, using aspirin, improved glucose tolerance in
the AnxA7-deficient strain, but also abrogated differences in insulin levels in wildtype and
AnxA7 KO-animals (Table 7a).
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In other studies, the increased PS exposure and eryptosis of Anxa7−/− erythrocytes
were associated with an increased adhesion to endothelial cells, an observation that might
be relevant for the adhesion of erythrocytes to the vascular wall and contribute to impaired
microcirculation during acute ischemic renal failure [379].
Enhanced PGE2 formation upon AnxA7 depletion appears relevant also for implan-
tation and fertility [380]. In women suffering from recurrent pregnancy loss, decreased
AnxA7 levels in endometrial biopsies during the midluteal window of implantation were
observed. This correlated with the viable Anxa7−/− strain showing significantly increased
implantation sites and litter sizes, indicating that ANXA7-mediated regulation of COX-
dependent PGE2 production contributes to regulating endometrial receptivity and implan-
tation [380].
8.4. AnxA7 and Brain Injury
Several studies addressed roles for AnxA7 in the brain (Table 7a). Possibly linked to
AnxA7-related impacts on the cellular handling of Ca2+ (Sections 8.1–8.3), lack of AnxA7
affected Ca2+ homeostasis and proliferation of primary Anxa7−/− astrocytes [381].
Other research suggested PKC-mediated phosphorylation of ANXA7 to promote
interaction with the SNARE proteins SNAP23 and SNAP25, facilitating membrane fusion
of exocytic vesicles with the plasma membrane [363,382]. These regulatory circuits may
be relevant for presynaptic glutamate release and postsynaptic N-methyl-D-aspartate
receptor trafficking, as proposed in studies examining brain tissue around hematoma after
intracerebral hemorrhage-induced brain injury [382]. In this model, ANXA7 knockdown
in vivo showed rescue effects on neuronal death, blood–brain barrier damage, brain edema,
neurobehavioral deficient, and inflammatory response. Similar results were also obtained
after subarachnoid hemorrhage-induced brain injury [383] and correlate with elevated
AnxA7 levels in traumatic brain injury [384], making AnxA7-based therapies a potentially
novel and alternative approach in the treatment of cerebrovascular disease (Table 7a).
8.5. Small Molecules Targeting AnxA7
Given the therapeutic potential of AnxA7 in a variety of disease settings, efforts to
screen small molecules identified 6-amino-2, 3-dihydro-3-hydroxymethyl-1, 4-benzoxazine
(ABO) to selectively bind and interfere with AnxA7 phosphorylation, altering AnxA7
localization, expression levels and its GTPase activity [385]. ABO was initially found to
induce AnxA7-dependent autophagy in cell-based studies [385]. In apoE−/− mice fed
a Western diet and treated with ABO, elevated AnxA7 levels in the aortic endothelium
correlated with increased autophagy and reduced apoptosis in this location. Moreover, this
was associated with reduced atherosclerotic plaque size and a more stable plaque pheno-
type, characterized by reduced lipid deposition, improved ratio of pro-/anti-inflammatory
macrophages, increased collagen and smooth muscle cell content, and less apoptosis [386].
The underlying mechanisms how ABO-mediated inhibition of AnxA7-GTPase activity
could reduce the size and stability of atherosclerotic plaques are complex, and include
altered expression of proteins involved in survival, metabolism, and autophagy [387,388],
respectively (Table 7a).
8.6. AnxA7 and Cancer
In human cancers, deletions at the Anxa7 gene locus on chromosome 10q21 are com-
mon, and a substantial number of studies identified AnxA7 and its GTPase activity as
a tumour suppressor with roles in cell death, motility and invasion in a variety of can-
cers [368,369]. For instance, ANXA7 expression is commonly lost in hormone-refractory
and locally recurrent metastatic prostate cancer, glioblastoma, and melanoma. On the other
hand, AnxA7 upregulation and tumour-promoting roles in the initiation and progression of
liver, colorectal, gastric, nasopharyngeal and breast cancer, have been reported. It would go
beyond the scope of this review to recapitulate these opposing findings in more detail, but
often the underlying mechanisms can be associated with alterations in Ca2+ homeostasis,
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Ca2+/GTP-dependent exocytic events, expression patterns of downstream effectors, as
well as AnxA7-dependent protein interactions [368,369].
Several in vivo studies support tumour suppressor roles for AnxA7 (Table 7b). For
instance, the initially generated heterozygous Anxa7+/− strain [361] revealed a cancer-
prone phenotype, with more than 20% of these mice developing spontaneous neoplasms,
with lymphosarcoma being most frequent, especially in females, indicating gender- and
possibly sex hormone -related differences [389]. This was accompanied by reduced expres-
sion of several tumour suppressors, DNA repair- and apoptosis-related genes, indicating
the development of genomic instability driving disease progression upon partial loss of
AnxA7 [389].
In efforts to develop therapeutic strategies against cancer cells expressing high integrin
β4 levels, which is common in multiple carcinomas, a small molecule ((S)-ethyl 1-(3-
(4-chlorophenoxy)-2-hydroxypropyl)-3- (4 methoxyphenyl)-1H-pyrazole-5-carboxylate)
(SEC) that increased AnxA7 GTPase activity similar to ABO was identified [390]. In
these studies, SEC-induced AnxA7 bound and promoted the nuclear translocation of
integrin β4, which inhibited the growth of A549 xenograft tumours in the avian embryo
model [390]. Likewise, SEC-mediated activation of AnxA7 GTPase effectively inhibited
prostate cancer metastasis in vivo [391]. In the latter, AnxA7-mediated activation of 5’ AMP-
activated protein kinase (AMPK) suppressed mammalian target of rapamycin complex 1
(mTORC1)/STAT3 signaling responsible for the expression of pro-metastatic genes [391].
On the other hand, AnxA7 upregulation was proposed to increase tumourgenicity and
lymph node metastasis in a hepatocarcinoma mouse model [392]. Vice versa, miR124-3p-
mediated downregulation of AnxA7 inhibited hepatocellular carcinoma growth, invasion
and lymphatic metastasis [393]. Silencing AnxA7 in a xenograft model for gastric cancer
induced apoptosis, altered the expression of apoptosis-mediating genes, and inhibited
tumour growth [394]. Altogether, AnxA7 has potential as a therapeutic target, but may
also serve as a biomarker for the diagnosis, treatment and prognosis of a number of
tumours [368,369] (Table 7b).
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Table 7. Phenotypes observed in AnxA7 in vivo models.
(a) AnxA7 and Various Disease Phenotypes
Tissue/Disease Model Phenotype Mechanism Ref
Development AnxA7 KO-mice 1 (neo cassette in intron 5-exon 6) Embryonal lethality due to cerebral haemorrhage Vascular development? [361]
Pancreas Heterozygous AnxA7 KO-mice 2 (neo cassette in intron 5-exon 6) Islet hyperplasia; β-cell hypertrophy; Defects in Ca
2+
homeostasis and insulin secretion
Reduced InsP3 receptor levels; Defective InsP3 receptor and
RyR-mediated Ca2+ release
[361,370]
Pancreas AnxA7 KO-mice 3 (neo cassette in exon 8) Normal pancreatic β-cells and insulin secretion Normal Ca2+ homeostasis [371]
Heart AnxA7 KO-mice 3
De-regulated cardiomyocyte contraction; Heart arrhythmia;
Cardiac remodelling
Defects in Ca2+ homeostasis; Impaired integrity of basement
cardiomyocyte membrane; Lack of collagen; Ca2+-dependent
NFAT activity
[371,372,374]
Eryptosis AnxA7 KO-mice 3
Erythrocyte resistance to osmotic shock; Protection against
plasmodium infection; Increased adhesion to endothelial cells




Uterus AnxA7 KO-mice 3 Endometrial receptivity and implantation Elevated COX-dependent PGE2 production [380]
Intestine AnxA7 KO-mice 3 Compromised glucocorticoid-induced gastric acid secretion Elevated COX-dependent PGE2 production [378]
Liver AnxA7 KO-mice 3 Decreased glucose tolerance Elevated plasma prostaglandins Elevated hepatic COX activity [366]
Brain AnxA7 KO-mice 3 Astrocyte proliferation Ca2+ homeostasis [381]
Brain injury Localized AnxA7 depletion in intracerebral- or subarachnoidhemorrhage- induced brain injury (rats, mice) Induction of neuronal apoptosis
Pre-synaptic glutamate release and post-synaptic NMDA
receptor trafficking [382,383]
Atherosclerosis HFD-fed ApoE KO-mice ABO treatment to target AnxA7-GTPase activity; Reducedplaque size; Increased plaque stability Suppression of PC-specific PLC in endothelial cells [386–388]
(b) AnxA7 and Cancer
Cancer Cancer-prone phenotype of heterozygous AnxA7 KO-mice 2
Genomic instability affecting tumour suppressor, DNA-repair,
apoptosis-related genes Tumour suppressor activity? Loss of AnxA7 GTPase activity? [389]
Adeno-carcinoma A549 xenografts in avian embryo model SEC treatment to increase AnxA7 GTPase activity Nuclear translocation of integrin β4 reduces tumour growth [390]
Prostate cancer PC3 xenografts SEC treatment to increase AnxA7 GTPase activity Inhibition of mTORC1/STAT3 signaling [391]
Hepatocellular carcinoma (HCC) AnxA7 overexpressing HCC xenografts Decreased tumourgenicity and metastasis Reduced VEGF levels [392]
HCC HCC xenografts Decreased tumourgenicity and metastasis miR-124-3p mediated AnxA7 downregulation [393]
Gastric cancer AnxA7 depletion in BGC823 xenografts Decreased tumour growth Increased apoptosis [394]
Abbreviations: ABO, 6-amino-2, 3-dihydro-3-hydroxymethyl-1, 4-benzoxazine; Akt, protein kinase B; Anx, annexin; apoE, apolipoprotein E; Ca2+, calcium; COX, cyclooxygenase; HCC, hepatocellular
carcinoma; HFD, high-fat diet; InsP3, inositol 1,4,5-trisphosphate; KO, knockout; miR, micro RNA; mTORC1, mammalian target of rapamycin complex 1; NFAT, nuclear factor of activated T cells; NMDA,
N-methyl-D-aspartate; PGE2, prostaglandin E2; PLC, phospholipase C; PC, phosphatidylcholine; PS, phosphatidylserine; RyR, ryanodine receptor; SEC, (S)-ethyl 1-(3-(4-chlorophenoxy)-2-hydroxypropyl)-3- (4
methoxyphenyl)-1H-pyrazole-5-carboxylate; STAT3, signal transducer and activator of transcription 3; VEGF, vascular endothelial growth factor. 1 non-viable AnxA7 knockout [355]. 2 viable heterozygous
AnxA7 knockout [355,383]. 3 viable AnxA7 knockout [365].
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9. AnxA8
AnxA8 is a less well-characterized member of the annexin family, and expressed at
low levels in the lung, liver, kidney, skin, placenta, and the cornea [395,396]. AnxA8 levels
are upregulated by leptin, during mammary gland involution and in acute promyelocytic
leukemia (APL) cells [396–398]. In these APL cells, all-trans retinoic acid-induced differ-
entiation was associated with AnxA8 downregulation, indicating a role in proliferation
and differentiation [398]. Indeed, over the years, elevated AnxA8 levels were reported
in a variety of cancers [397–399], and as shown upon in vivo knockdown in endometrial
cells of the uterine horn of mice, possibly promoting cell proliferation via Akt signaling
pathways [400] (Table 8).
AnxA8 controls the sorting and transport of late endosomal cargo [401], a function
that appears critical for leucocyte adhesion to activated endothelium, which requires stabi-
lization of the leukocyte receptor P-selectin on the endothelial cell surface by CD63. CD63
is located in late endosomes and in order to fulfill this function, needs to be transported
to the cell surface. Strikingly, cell surface delivery of CD63 in AnxA8-deficient human
umbilical vein endothelial cells was strongly reduced and correlated with compromised
leukocyte adhesiveness in inflammatory-activated endothelial venules of AnxA8-deficient
mice [402] (Table 8).
Table 8. Phenotypes observed in AnxA8 in vivo models.





































Abbreviations: Akt, protein kinase B; Anx, annexin; KO, knockout.
10. AnxA9
AnxA9 was initially identified in expression libraries from fetal liver/spleen [403]
and shares a high sequence homology with AnxA2. Yet, AnxA9 is an atypical annexin, as
inactivated type II-Ca2+ binding sites within its core domain confered Ca2+-independent
membrane and phospholipid-binding properties [404]. Together with its low abundance
during mouse development and in adult organs, in particular spleen and liver [405],
this suggests a Ca2+-independent and rather specific role unrelated to membrane scaffold-
ing functions proposed for the other annexins. Interestingly, autoantibodies isolated from
patients with pemphigus vulgaris, a rare skin autoimmune disease, cross-reacted with
AnxA9 [406]. However, the exact role of AnxA9 in this disease has yet to be clarified and
an AnxA9 KO-mouse model does not exist.
11. AnxA10
Annexin A10 was identified only two decades ago [407] and is mainly expressed
in epithelia of the gastrointestinal tract [408]. Its localization and function, alike AnxA8,
remains to be fully understood, but unlike other annexins, AnxA10 displays functions in-
dependent of Ca2+ and/or membrane-binding and was found in nuclear bodies interacting
with mRNA-binding proteins, possibly involved in mRNA regulation or processing [409].
Homozygous deletion or downregulation of AnxA10 in several cancers, including blad-
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der, gastric, pancreas and liver, correlated with progression and poor survival, indicating
potential as a diagnostic marker and tumour suppressor [408,410–412].
To our knowledge, up to date, only two studies utilized gene depletion approaches
to examine AnxA10 functions in vivo, both addressing neuropathic pain. In mice, spinal
nerve ligation (SNL) -induced neuropathic pain was associated with AnxA10 upregulation
in the spinal cord. AnxA10 colocalized with neuronal and astrocyte markers and upon
AnxA10 depletion, SNL-induced pain was attenuated [413]. Similarly, AnxA10 knockdown
in the spinal cord of rats suppressed SNL-induced hyperalgesia, possibly by blocking
the activation of pro-inflammatory mediators, including NFκB, TNFα and IL-1β and
metalloproteases [414] (Table 9).
Table 9. Phenotypes observed in AnxA10 in vivo models.
































Abbreviations: Anx, annexin; IL1β, interleukin 1β; KO, knockout; NFκB, nuclear factor kappa B; TNFα, tumor
necrosis factor α; SNL, spinal nerve ligation.
12. AnxA11
AnxA11 is ubiquitously expressed in a wide variety of tissues with diverse functions
in cytoplasmic and nuclear locations. Earlier studies identified AnxA11 to associate with
the nuclear envelope in a Ca2+- and cell cycle-dependent manner, binding to S100A6 (cal-
cyclin) [415], an interaction possibly relevant for cell growth and differentiation [415–417].
During cell cycle progression, AnxA11 translocates from the nucleus to the spindle poles
in metaphase and to the spindle midzone in anaphase, enabling midbody formation and
completion of cytokinesis [417]. In the cytosol, AnxA11 binds to secretory vesicles in a
Ca2+-dependent manner, regulating Ca2+-dependent exocytic events, such as Ca2+-inducible
insulin secretion in pancreatic β-cells [418]. In the early secretory pathway, interaction of
AnxA11 with apoptosis-linked gene-2 (Alg-2) and Sec31A contributes to the exit of cargo
from the endoplasmic reticulum for transport to the Golgi apparatus [419].
12.1. AnxA11 and Cancer
Although confirmation from in vivo studies in mouse models are still limited, in
certain cancers AnxA11 up- or downregulation appears to be linked to disease progression
and development of drug resistance [93] (Table 10). For instance, in ovarian cancer AnxA11
downregulation correlated with tumour recurrence and was associated with cisplatin resis-
tance [420]. In a mouse model for human hepatocellular carcinoma, ANXA11 upregulation
was associated with increased Akt activation and contributed to tumour growth and pro-
gression [421]. Species and/or cancer-subtype specific differences may exist, as ANXA11
downregulation in the murine Hca-P hepatocarcinoma cell line promoted in vivo tumour
growth, lymph node metastatic potential and chemoresistance towards 5-fluorouracil [422].
Strikingly, a single nucleotide polymorphism (SNP) in the Anxa11 gene, causing a
mutation at position 230 (R230C), was associated with an increase in the overall response
rate of metastatic colorectal cancer patients to bevacizumab, an angiogenesis inhibitor [423].
In support of these findings, the R230C variant was more susceptible to bevacizumab-
induced tumour suppression when examining xenograft models [424]. The underlying
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mechanism remains to be clarified, but this Anxa11 SNP (rs1049550) may serve to im-
prove the identification of metastatic colorectal cancer patients sensitive to bevacizumab
regimens [425].
Table 10. Phenotypes observed in AnxA11 in vivo models.

















































Abbreviations: 5-fluorouracil, 5-FU; Akt, protein kinase B; Anx, annexin; HCC, hepatocellular carcinoma; KO,
knockout; miR, micro RNA.
12.2. AnxA11 and Autoimmune Diseases
Besides the link of several annexins, including AnxA11, to the autoimmune disease
SLE, Anxa11 polymorphism were found in other autoimmune disorders, such as granulo-
matous disease [426]. Furthermore, several genome-wide studies in recent years identified
a genetic association of the R230C variant with sarcoidosis [427,428].
Finally, Anxa11 mutations were found in the rare and related neurodegenerative
diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Numerous
mutations in both the N-terminal tail and the C-terminal membrane binding region of
Anxa11 have now been described and may account for up to 6% of familial ALS in Chinese
populations [429–432].
Recent studies provided mechanistic insight, proposing disease-associated Anxa11
mutations to contribute to ALS pathogenesis through dysregulated Ca2+ homeostasis and
abnormal protein aggregation [433]. Furthermore, Anxa11 mutations in ALS altered several
fundamental AnxA11 properties. In primary rat neurons, but also in an in vivo zebrafish
model, ANXA11 acted as a molecular tether, coupling RNA granules to lysosomes, en-
abling long-distance transport of RNA along axons [432]. This novel relationship between
lysosomes and RNA was disrupted in ALS-associated Anxa11 mutations, as RNA granules
could not dock onto lysosomes for axonal transport. Hence, Anxa11 mutations may re-
duce delivery of essential mRNAs to distal regions of the neuron, which may dysregulate
neuronal homeostasis and synaptic activity [432].
13. Conclusions
Exposure of annexin KO-mice or animals harbouring implanted annexin-deficient cell
lines to a variety of disease-related stress conditions revealed important biological functions
of individual annexins (Tables 1–10). These animal models enabled the characterization of
prominent extracellular activities for several annexins (i.e., AnxA1, A2, A5). This group of
annexins might in the future serve as diagnostic or therapeutic tools—maybe in combination
with nanoparticles or radio- and fluorescence-labeling. Peptide or protein-based approaches
could be suitable to facilitate targeted delivery in vivo. AnxA1 and its interaction with FPR
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receptors has potentially numerous therapeutic applications in the context of acute and
chronic inflammation and cancer (Sections 2.1–2.4). The extracellular functions of AnxA2
are therapeutically relevant to control fibrinolysis and neoangiogenesis in several diseases
(Sections 3.1 and 3.3). The strong affinity of AnxA5 for PS on apoptotic cells can be applied
in a large range of diagnostic and therapeutic approaches (Sections 6.2–6.6).
Phenotypes associated with the annexins AnxA3, A4, A6, A7, A8, A10 and A11 are
often linked to Ca2+ homeostasis, as well as their membrane organizing and scaffolding
properties, affecting receptors, transporters, or ion channels and their communication with
cellular protein networks. However, the multifunctionality of these annexins render the
development of targeted approaches difficult and fine-tuned local modulation of specific
protein-protein or protein-lipid interactions remain hard to achieve. Nevertheless, drug
targeting the GTPase activity of AnxA7 via small molecules hold promise for treatment of
certain cancers and cardiovascular diseases (Sections 8.5 and 8.6). In addition, drug-induced
AnxA6 upregulation, delivery of recombinant AnxA6 or AnxA6-targeting antibodies might
lead to the development of novel treatment options in lipid disorders, liver dysfunction,
several cancers and muscular damage (Sections 7.4–7.6). Finally, the controlled up- or
downregulation of annexins using viral gene delivery, small pharmacological molecules or
CRISPR/Cas technology could provide opportunities for therapy in certain organs, such
as liver and muscle, but also in the context of many cancer-related settings. Their intra-
and extracellular expression levels could have diagnostic value, possibly linked to cancer
progression and/or anticancer drug resistance (Sections 3.3, 4.1, 5.1, 6.4 and 7.5).
On the other hand, the actual genetic evidence to support the relevance of annexins in
human disease is still sparse. In earlier studies, annexin anomalities, also called ‘annex-
inopathies’, were initially reported in two disease states, identifying AnxA2 overexpression
in patients with a haemorrhagic form of acute promyelocytic leukaemia, and AnxA5 down-
regulation on placental trophoblasts in the antiphospholipid syndrome [434,435]. Over re-
cent years, a substantial number of additional studies identified correlations between
disease progression and expression patterns of individual annexins; as is the case in many
cancer and other acute and chronic diseases [1–3,21–23,90,116,226,242,342,343,368,369].
However, aided by deep sequencing data, various SNPs were identified, suggesting a po-
tential involvement of AnxA1 in Alzheimer’s disease [436], and revealed roles for AnxA2
in sickle cell disease [119,120], but also cardiovascular risk due to elevated LDL choles-
terol [114,149]. Similarly, the identification of SNPs in the Anxa3 gene locus may imply roles
in gastric cancer [437]. SNPs in the Anxa5 gene are associated with the risk of pregnancy-
related venous thrombosis, preeclampsia [438,439] and malignant melanoma [440]. Certain
SNPs in the Anxa6 locus have been linked to psoriasis [441,442], while another polymor-
phism in the Anxa6 coding region causes a dominant-negative deletion mutant in a mouse
model for muscle dystrophy that interferes with membrane repair [295].
Finally, and most convincingly, the R230C variant and several other SNPs in the N-
and C-terminal region of Anxa11 have been associated with neurodegenerative and autoim-
mune disorders, such as ALS [429–433] and sarcoidosis [427–429]. These polymorphism
could be explored further and might serve as a marker for anticancer drug performance
in metastatic colorectal cancer [423–425]. These observations, together with advanced in-
travital imaging techniques, –omics approaches, molecular modelling and small molecule
development, in combination with tissue specific knock-in/KO-mouse models could open
exciting perspectives to further pursue annexin-based therapeutic strategies.
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